

SCOPE: a scorecard for osteoporosis in Europe

J. A. Kanis • F. Borgström • J. Compston •
K. Dreinhöfer • E. Nolte • L. Jonsson • W. F. Lems •
E. V. McCloskey • R. Rizzoli • J. Stenmark

Received: 25 March 2013 / Accepted: 14 May 2013 / Published online: 13 September 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract

Summary The scorecard summarises key indicators of the burden of osteoporosis and its management in each of the member states of the European Union. The resulting scorecard elements were then assembled on a single sheet to provide a unique overview of osteoporosis in Europe.

Introduction The scorecard for osteoporosis in Europe (SCOPE) is an independent project that seeks to raise awareness of osteoporosis care in Europe. The aim of this project was to develop a scorecard and background documents to draw attention to gaps and inequalities in the provision of primary and secondary prevention of fractures due to osteoporosis.

Methods The SCOPE panel reviewed the information available on osteoporosis and the resulting fractures for

each of the 27 countries of the European Union (EU27). The information researched covered four domains: background information (e.g. the burden of osteoporosis and fractures), policy framework, service provision and service uptake e.g. the proportion of men and women at high risk that do not receive treatment (the treatment gap).

Results There was a marked difference in fracture risk among the EU27. Of concern was the marked heterogeneity in the policy framework, service provision and service uptake for osteoporotic fracture that bore little relation to the fracture burden. For example, despite the wide availability of treatments to prevent fractures, in the majority of the EU27, only a minority of patients at high risk receive treatment for osteoporosis even after their first fracture. The elements of each domain in each country were

J. A. Kanis
University of Sheffield Medical School, Sheffield, UK

J. A. Kanis • J. Stenmark
International Osteoporosis Foundation, Nyon, Switzerland

F. Borgström
LIME/MMC, Karolinska Institutet, Stockholm, Sweden

J. Compston
Department of Medicine, University of Cambridge
School of Clinical Medicine, Cambridge, UK

K. Dreinhöfer
CSSB, Charité Universitätsmedizin Berlin and Medical Park
Berlin Humboldtmühle, Berlin, Germany

E. Nolte
Health and Healthcare Policy Program, RAND Europe,
Cambridge, UK

L. Jonsson
OptumInsight, Stockholm, Sweden

W. F. Lems
Vrije Universiteit University Medical Center, Amsterdam,
The Netherlands

E. V. McCloskey
University of Sheffield Academic Unit of Bone Metabolism,
Metabolic Bone Centre, Northern General Hospital, Sheffield, UK

R. Rizzoli
Division of Bone Diseases, Geneva University Hospitals
and Faculty of Medicine, Geneva, Switzerland

J. A. Kanis (✉)
WHO Collaborating Centre for Metabolic Bone Diseases,
University of Sheffield Medical School, Beech Hill Road,
Sheffield S10 2RX, UK
e-mail: w.j.pontefract@sheffield.ac.uk

scored and coded using a traffic light system (red, orange, green) and used to synthesise a scorecard. The resulting scorecard elements were then assembled on a single sheet to provide a unique overview of osteoporosis in Europe.

Conclusions The scorecard will enable healthcare professionals and policy makers to assess their country's general approach to the disease and provide indicators to inform future provision of healthcare.

Keywords SCOPE · Scorecard · Osteoporosis · Burden of disease · Cost · European Union · Treatment uptake · Treatment gap · Service provision · Service uptake · Policy framework

SCOPE

Scorecard for osteoporosis in Europe

About SCOPE

The ScoreCard for *Osteoporosis in Europe* (SCOPE) is an independent project that seeks to raise awareness of osteoporosis care in Europe. SCOPE permits an in depth comparison of the quality of care of osteoporosis across the 27 member states of the European Union (EU27).

Osteoporosis is a complex disease that can be treated and managed in a number of ways. Improvements in medication and diagnostic techniques in the past 25 years have served to reduce the risk of osteoporotic fractures. In Europe, however, research has shown significant heterogeneity in the different national approaches to the management of the disease.

The scorecard summarises key indicators of the burden of osteoporosis and its management in each member state of the European Union to draw attention to the disparities in healthcare provision that can serve in the setting of benchmarks to inform patients, healthcare providers and policy makers in the EU.

The aim of this scorecard is to stimulate a balanced, common and optimal approach to the management of osteoporosis throughout the EU.

Table of contents

Letter to all Europeans	2
Introduction	3
1. Burden of disease	6
2. Policy framework	23
3. Service provision	33
4. Service uptake	48

Scorecard	59
Acknowledgments	61
Abbreviations and glossary	62

A letter to all Europeans

The statistics are startling.

One in three women and at least one in six men will suffer an osteoporotic fracture in their lifetime, and it is estimated that more than ten million men and women are at high risk of osteoporotic fractures in the European Union.

Osteoporosis and the 3.5 million fractures it causes cost the healthcare systems of Europe in excess of €39 billion each year based on data for 2010. But numbers don't tell the full story. For the individuals who suffer fractures as a result of the disease, the stories are personal. Pain, disability, reduced mobility and long-term disability are all too frequent. Additionally, fractures related to osteoporosis result in early death. About 43,000 deaths occur each year in Europe as a direct consequence of hip or spine fractures.

The primary purpose of the scorecard for osteoporosis in Europe is to help individuals reduce their risk of osteoporosis and to ensure that all Europeans have access to the best diagnosis and treatment. Components that are critical to achieving this goal include government policy, access to assessment of risk and access to medications. This scorecard allows Europeans to measure how well their country is able to access these elements through the publicly funded healthcare systems. It also provides a benchmark to measure future progress.

Our research reveals that facilities and access to testing for osteoporosis are far from adequate. Access to drug treatment that can help prevent fractures varies markedly from country to country; in some member states, individuals with osteoporosis are restricted from accessing effective treatment options. Less than half of women at high risk of fracture are treated despite the high cost of fractures and the availability of affordable medications.

Action is required. The national osteoporosis societies of the International Osteoporosis Foundation are calling for a Europe-wide strategy and parallel national strategies to provide coordinated osteoporosis care and to reduce debilitating fractures and their impact on individual lives and the healthcare system. We welcome the opportunity to partner with governments at the national and European level to develop and implement these strategies. Together we can improve the bone health of all in Europe.




John A Kanis




F Borgstrom



J Compston


John A Kanis
on behalf of K Dreinhofer


E Nolte



L Jonsson



W Lems



EV McCloskey



R Rizzoli



J Stenmark

Introduction

The basis for SCOPE

SCOPE comprises an independent panel of experts that have considered the information available on the burden of osteoporosis and healthcare provision and uptake in the EU27. SCOPE draws on independent research from two major sources. The first was a series of regional audits of the International Osteoporosis Foundation (IOF) [1–3]. This information base was broadened and updated by IOF to inform the SCOPE panel members through its outreach to over 30 national osteoporosis societies throughout Europe. The second major resource was a comprehensive report undertaken by the IOF and the European Federation of Pharmaceutical Industry Associations (EFPIA) on the burden of osteoporosis in the largest countries of the EU [4]. This was subsequently extended to all counties of the EU [5, 6] and made available to the panel.

From the information available, the panel developed indicators of osteoporosis that could be applied to each member state, categorised as:

Burden of disease—including the burden of osteoporosis, fractures and forecasts for the future

Policy framework—such as the availability of public health programmes

Service provision—including assessment and treatments of osteoporosis

Service uptake—e.g. the proportion of men and women at high risk that do not receive treatment (treatment gap).

Comparisons of indicators across countries are often limited by a lack of consistency of information retrieved across countries. One of the strengths of the resource documents considered by the panel is the consistency of the approach in

documenting the burden of disease, wherever possible, by the use of country-specific information. The Scorecard Panel and the IOF invested substantial efforts to ensure that the European audits were updated by means of a structured questionnaire that was sent to all IOF national societies and key opinion leaders in each country. Discrepancies and ambiguities were resolved by correspondence. The panel recognised that consistency does not necessarily equal accuracy and, where information across countries is based only on opinion, this has been highlighted. The questionnaire is available on the web site of the IOF (<http://www.iofbonehealth.org/>).

For each domain, a synthesis was summarised and tabular information provided for each member state which appears in the body of the report. For key indicators, termed scorecard elements, the information was scored and the basis for the score allocation provided. For example, the remaining lifetime risk of a hip fracture at the age of 50 years ranged from 7.0 to 25.1 % in women from the different countries of the EU. Countries were categorised by tertile of risk. High risk countries were colour coded red, intermediate risk coded orange and low-risk countries coded green. A similar 'traffic light' approach was applied to each element in each domain. The resulting scorecard elements were then assembled on a single sheet to provide a unique overview of osteoporosis in Europe. It will enable healthcare professionals and policy makers to assess their country's general approach to the disease and provide indicators to inform future provision of healthcare.

Some caveats are appropriate in the interpretation of scores. Green is not necessarily 'good' and red is not necessarily 'bad'. An example of the former is the uptake of fracture liaison services. Whereas countries coded green have up to 10 % of hospitals with such a service, the panel would consider that 50 % or more hospitals would be an appropriate target. Coding all countries red would, however, not permit the comparative performance of one country against another. Other examples are highlighted in the text.

Osteoporosis

Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased bone fragility and increased fracture risk [7]. The publication of a World Health Organization (WHO) report on the assessment of fracture risk and its application to screening for postmenopausal osteoporosis in 1994 provided diagnostic criteria for osteoporosis based on the measurement of bone mineral density (BMD) and recognised osteoporosis as an established and well-defined disease that affected more than 75 million people in the United States, Europe and Japan [8].

The diagnostic criterion for osteoporosis is based on the measurement of BMD [9]. Bone mineral density is most often described as a *T* score that describes the number of SDs by which the BMD in an individual differs from the mean value expected in young healthy women. The operational definition of is defined as a value for BMD 2.5 SD or more below the young female adult mean (*T* score less than or equal to -2.5 SD). BMD at the femoral neck is the international reference standard [10]. The consequences of low BMD reside in the fractures that arise. The relationship between BMD and fracture is continuous in that the lower the BMD, the higher the fracture risk [11].

Osteoporotic fractures

The most common fractures associated with osteoporosis are those at the hip, spine, forearm and humerus but many other fractures after the age of 50 years are associated with low BMD and should be regarded as osteoporotic [12]. These include fractures of the ribs, tibia, pelvis and other femoral fractures. The causation of fractures is not solely dependent on BMD but is multifactorial. Many factors such as liability to falling, age etc. contribute to the risk of fracture. Thus, not all fragility fractures occur in individuals with a BMD *T* score of -2.5 SD, and the terms osteoporosis, fragility fracture and osteoporotic fractures have inherent ambiguities. For the purpose of this report, the term osteoporosis is used in a generic sense rather than a specific sense unless otherwise specified. For example the 'cost of osteoporosis' refers to the cost of fractures at sites associated with osteoporosis irrespective of the *T* score.

The incidence of fragility fractures increases markedly with age, though the rate of rise with age differs for different fracture outcomes. For this reason, the proportion of fractures at any site also varies with age. For example, forearm fractures account for a greater proportion at younger ages than in the elderly. Conversely, hip fractures are rare at the age of 50 years but become the predominant osteoporosis fracture from the age of 75 years. In women, the median age for distal forearm fractures is around 65 years and for hip fracture, 80 years. Thus, both the number of fractures and the type of fracture are critically dependent on the age of the populations at risk.

Hip fracture is the most serious osteoporotic fracture. Hip fracture is painful and nearly always necessitates hospitalisation and surgical intervention. Up to 20 % of patients die in the first year following hip fracture, mostly as a result of serious underlying medical conditions [13], and less than half of survivors regain

the level of function that they had prior to the hip fracture [14]. Thus, not all deaths associated with hip fracture are due to the hip fracture event and it is estimated that approximately 30 % of deaths are causally related. When this is taken into account, hip fracture causes more deaths than road traffic accidents in Sweden and about the same number as those caused by breast cancer [15].

References

1. International Osteoporosis Foundation (2001) Osteoporosis in the European Community: A call to action. An audit of policy developments since 1998. International Osteoporosis Foundation, Nyon, Switzerland.
2. International Osteoporosis Foundation (1998) Report on osteoporosis in the European Community: A call to action. Action for prevention. International Osteoporosis Foundation, Nyon, Switzerland
3. International Osteoporosis Foundation (2010) Osteoporosis in the European Union in 2008. Ten years of progress and ongoing challenges. Updated Aug 2010. International Osteoporosis Foundation, Nyon. Available at www.iofbonehealth.org, accessed 23rd Sept 2012
4. Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jönsson B (2011) Osteoporosis; Burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59–155. DOI [10.1007/s11657-011-0060-1](https://doi.org/10.1007/s11657-011-0060-1)
5. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos, in press
6. Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA and the EU review panel of the IOF (2013) Osteoporosis in the European Union: A compendium of country-specific reports. Arch Osteoporos, in press
7. Anonymous (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94: 646–50
8. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva
9. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9: 1137–41
10. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42: 467–75
11. Johnell O, Kanis JA, Oden A et al. (2005) Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 20:1185–1194
12. Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR (1991) Which fractures are associated with low appendicular bone mass in elderly women? The study of osteoporotic fractures research group. Ann Intern Med 115: 837–42
13. Keene GS, Parker MJ, Pryor GA (1993) Mortality and morbidity after hip fractures. BMJ 307: 1248–50
14. Melton LJ 3rd (2003) Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 18: 1139–41
15. Kanis JA, Oden A, Johnell O, De Laet C, Jönsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32: 468–73

Chapter 1. Burden of disease

1a Economic framework

Domain

Burden of disease—background information

Background and aims

Cost of illness studies provide no direct guidance on how resources should be allocated, but may provide relevant information concerning the consequences of a disease that may inform policy. Such data may aid decisions concerning societal resource allocation for research, development, and funding of new treatments. Results from cost-of-illness

studies can also be utilised to assess the long-term consequences and value of medical progress.

The objective of this background section is to estimate the current cost of osteoporotic fracture in the countries of the European Union set against the wealth of the nation and the healthcare spend of that wealth. A more detailed consideration of the cost is given in Chapter 1b.

Methods

Direct costs of fractures in men and women from the EU27 aged 50 years or more were expressed as a proportion of total health care spending in the respective

Table 1 Cost of osteoporotic fractures in relation to the population and health care spending (2010)

Country	Population (000)	Health care spending (€000,000)	Health care spending (% GDP)	Health care spending (€/capita)	Fracture cost (% health care spending)
Austria	8,392	31,000	10.2	3,741	2.5
Belgium	10,712	42,000	9.9	3,903	1.5
Bulgaria	7,493	2,700	7.2	354	1.6
Cyprus	1,103	1,000	6.2	937	5.2
Czech Republic	10,493	11,000	6.9	1,087	2.2
Denmark	5,551	26,000	10.8	4,759	4.0
Estonia	1,339	1,000	5.2	747	3.0
Finland	5,365	18,000	8.2	3,263	2.2
France	62,634	227,000	11.0	3,617	2.1
Germany	82,056	281,000	10.6	3,418	3.2
Greece	11,358	24,000	9.5	2,126	2.9
Hungary	9,985	7,000	8.3	709	3.6
Ireland	4,470	15,000	7.5	3,399	1.5
Italy	60,098	148,000	9.0	2,461	4.7
Latvia	2,252	1,000	6.6	520	3.2
Lithuania	3,325	2,000	6.2	546	2.6
Luxembourg	506	3,000	7.3	6,235	0.7
Malta	416	500	8.4	1,108	3.8
Netherlands	16,610	64,000	9.4	3,829	1.3
Poland	38,276	25,000	6.2	660	2.4
Portugal	10,676	19,000	10.2	1,826	3.0
Romania	21,486	7,000	4.5	309	2.0
Slovakia	5,463	3,000	7.1	1,092	3.6
Slovenia	2,028	6,000	8.4	1,485	0.9
Spain	45,317	102,000	8.4	2,247	2.8
Sweden	9,294	34,000	9.2	3,709	4.3
UK	61,899	159,000	8.2	2,564	3.4
EU27	498,597	1,260,000		2,528	3.0

Healthcare spend on osteoporotic fractures (% total)




Fig. 1 Proportion (%) of the total direct healthcare spend in the EU27 countries allocated to osteoporotic fractures [3]

country [1] and as the cost per capita of the general population [2, 3].

Results

Health care spending varied markedly between countries, ranging from €500 million in Malta to €281 billion in Germany (Table 1). The total spend on healthcare in the European Union amounted to €1,260 billion, with the cost of osteoporotic fractures representing approximately 3 % of the healthcare spend (€37.4 billion in 2010). This clearly demonstrates a substantial impact on the present healthcare budget

The share of health care spending allocated to osteoporosis varied across countries, ranging from 0.7 % in Luxembourg to 5.2 % in Cyprus (Fig. 1). As might be expected there was a significant but modest relationship between the amount spent on osteoporosis, GDP and the incidence of osteoporotic fractures.

The estimated cost of osteoporosis may be compared to the cost of other diseases. However, given that the EU27 is a relatively new construct, few directly comparable studies exist. Furthermore, methodological differences render some studies difficult to compare. However, a few studies are available conducted in a similar geographic area with comparable methodology.

In a report issued by the European Brain Council, the yearly societal costs for a number of brain disorders in the EU27 were estimated at €105 billion for dementia, €43.5 billion for headache, €14.6 billion for multiple sclerosis, and €13.9 billion for Parkinson's disease [4].

The cost of coronary heart disease and cerebrovascular disease in the European Union (25 countries) has been estimated at approximately €45 billion and €34 billion, respectively, at 2003 prices [4]. The cost of epilepsy in the

European Union (25 countries) has been estimated at €15.5 billion at 2004 prices. Healthcare costs comprised 18 % of costs, whereas direct medical costs and productivity losses represented 27 % and 55 %, respectively [5]. Thus, in relation to other common non-communicable diseases osteoporosis has major economic consequences for society.

Score allocation

None—not a score card element

Comment

It should be noted that not all fracture-related costs come from the countries' healthcare budgets (e.g. long-term care and variable reimbursement policies). Data on healthcare spending are for 2006.

References

1. World Health Organization (2009) World Health Statistics. (2009) 107. Health expenditure www.who.int/whosis/whostat/EN_WHS09_Table7.pdf Accessed 21st December 2011
2. UN (2010) Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat (2010) World Population Prospects: The 2010 Revision, <http://esa.un.org/unpd/wpp/index.htm> Accessed 16th December 2011
3. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Archives of Osteoporosis, in press
4. Gustavsson A, Svensson M, Jacobi F, et al. (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:718–779
5. Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P (2007) Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 48:2224–2233

1b Healthcare cost of osteoporotic fractures

Domain

Burden of disease—background information

Background and aims

Cost of illness studies can take on a societal perspective (includes all cost carried directly or indirectly by society) or a payer perspective (usually includes all costs carried by the healthcare

and social system). Both play an important role in the understanding of disease implications and may aid decisions concerning societal resource allocation for research, development, and funding of new treatments. Results from cost of illness studies can also be utilised to assess the value of medical progress.

The main objective of this section is to provide detail on the current cost of osteoporotic fractures in the countries of the European Union.

Methods

The cost of osteoporotic fractures was first determined without intangible costs (i.e. the monetary value of QALYs lost due to death and disability) [1]. Costs of fracture-related productivity losses were not included because they are only incurred in patients below retirement age—median age 60 years in Europe [2]—and are less than 1 % of hip fracture cost in Sweden [3].

Empirical but incomplete cost estimates were available for Austria, Belgium, Czech Republic, Denmark, Finland, Germany, Ireland, Italy, Netherlands, Portugal Slovenia, Sweden and the UK. For countries where fracture costs

were not found, the costs were imputed from the nearest country available by adjusting for differences in healthcare price levels between the relevant countries.

Costs were divided into the direct cost of fractures in 2010, the ongoing cost in 2010 of fractures occurring before 2010 ('long-term disability'), and the cost of intervention for osteoporosis. It was conservatively assumed that fractures other than those at the hip did not incur any longer-term costs after the first year. Hip fracture costs in the second and following years after the event were based on the proportion of patients that become dependent in the long-term.

The health burden of osteoporosis was additionally measured in terms QALYs lost. The QALY is a multi-dimensional outcome measure that incorporates both the quality (health related) and quantity (length) of life. The value of a QALY was set at value of 2× GDP per capita [4].

Results

The direct cost of osteoporosis in the EU27 from the fractures that occurred in 2010 was €24.6 billion (Table 2).

Table 2 Cost of osteoporosis in the EU27 in 2010 (€ million, 2010) [1]

Country	Incident fractures	Long-term disability	Intervention	Total	Cost per capita (€)	QALYs lost (€m)
Austria	540	229	30	799	95	1 903
Belgium	419	157	29	606	57	1 734
Bulgaria	30	11	1	42	6	118
Cyprus	34	7	12	52	47	78
Czech Republic	165	56	53	273	26	630
Denmark	718	300	37	1,055	190	1 704
Estonia	22	7	1	30	22	59
Finland	269	104	10	383	71	829
France	3,179	1,329	346	4,853	77	8 309
Germany	6,617	2,055	336	9,008	110	14 927
Greece	488	102	91	680	60	1 263
Hungary	127	30	40	197	20	464
Ireland	125	62	35	223	50	426
Italy	4,269	2,402	361	7,032	117	8 771
Latvia	29	7	2	38	17	72
Lithuania	32	12	3	47	14	81
Luxembourg	15	4	2	22	43	148
Malta	11	4	2	17	41	24
Netherlands	360	434	29	824	50	1 863
Poland	355	162	76	593	16	991
Portugal	293	264	20	577	54	580
Romania	88	35	7	129	6	339
Slovakia	76	19	11	107	20	283
Slovenia	36	13	7	56	28	168
Spain	1,372	1,055	414	2,842	63	3 271
Sweden	927	529	29	1,486	160	2 666
UK	3,977	1,328	103	5,408	87	8 698
EU27	24,574	10,718	2,087	37,378	75	57 243

To this is added the ongoing cost in 2010 incurred by fractures that occurred before 2010 which amounted to €10.7 billion (long-term disability). The cost of pharmacological intervention (assessment and treatment) was €2.1 billion. Thus, the total direct cost in the EU27 (excluding the value of QALYs lost) amounted to €37.4 billion in 2010. First year, subsequent year, and pharmacological costs accounted for 66, 29 and 5 % of the costs respectively.

Whilst the proportion of costs for pharmacological intervention to total costs was low on average, some inter-country variation was observed: the lowest proportion of costs attributable to intervention was observed in Sweden (2 %) and the highest costs in Hungary (4.7 %). Hip fractures were estimated to account for 54 % of the total costs, other fractures 39 %, vertebral fractures 5 %, and forearm fractures 2 %.

On average, the direct cost of osteoporotic fractures was €75 for each individual in the EU27. There was a large variation in the 'osteoporosis tax' (cost per capita) which was highest in Denmark (€188/person) and Sweden (€159) and lowest in Bulgaria (€6) and Romania (€6). The heterogeneity of this cost is in part related to the incidence of fracture ($r=0.67$, $p=0.001$) and the healthcare spend per capita ($r=0.63$, $p=0.004$).

The cost of QALYs lost in the EU27 was substantial amounting to €57.2 billion, giving a total cost of €94.6 billion in 2010. Intervention costs amounted to 2 % of the total cost (Fig. 2) and 5 % of the direct costs.

Score allocation

None—not a score card element

Comment

There are few directly comparable studies in other non-communicable diseases that exist.

For coronary heart disease, healthcare costs, productivity losses, and informal care comprised 51, 34 and 15 %, respectively. Costs for pharmacological treatment accounted for 12 % of the total cost, substantially higher




Fig. 2 Components (%) of the cost of osteoporosis and fractures [1]

than that for osteoporosis. For cerebrovascular disease, healthcare costs, productivity losses, and informal care comprised 61, 18 and 21 %, respectively. The cost for pharmacological treatment accounted for 3 % of the total cost for cerebrovascular disease [5], somewhat lower than that for osteoporosis.

References

1. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos, in press
2. European Commission (2012) Eurostat. Statistics database. Data retrieved in November, 2011; <http://epp.eurostat.ec.europa.eu>
3. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7: 390–406
4. Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C. (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459–71.
5. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M (2006) Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 27:1610–1619

1c Men and women with osteoporosis

Domain

Burden of disease—background information

Background and aims

Osteoporosis is diagnosed using dual-energy X-ray absorptiometry (DXA) to measure bone mineral density (BMD). The diagnostic reference site is the femoral neck using the NHANES III reference data [1]. Osteoporosis is diagnosed when the BMD measured at the femoral neck is more than 2.5 standard deviations below the average value of the young white female population [2]. The aim of this background information was to document the burden of osteoporosis as judged by densitometric criteria.

Methods

Accurate estimates of the prevalence of osteoporosis require country-specific data on the distribution of femoral neck BMD. However, large population-based reference data are lacking in the EU27 countries. For the purposes of this

report, it is assumed that the mean femoral neck BMD is similar across EU countries at the age of 50 years as is the rate of bone loss at the femoral neck with age. The same assumptions have been used elsewhere [3–8]. On this basis, the prevalence of osteoporosis was calculated from the age- and sex-specific BMD in the NHANES III study. These prevalence estimates were then applied to the population demography in each EU country [9].

Results

In 2010, there were approximately 27.6 million men and women with osteoporosis in the EU27, of which 5,500,000 were men and 22,100,000 were women, i.e. there were four times as many women with osteoporosis as there were men. Of all member states, Germany was estimated to have the highest number of individuals with osteoporosis with approximately 1 million osteoporotic men and 4 million osteoporotic women.

Overall, the prevalence of osteoporosis was 6.6 and 22.1 % in men and women aged 50 years or more (Table 3). In men over the age of 50 years, the prevalence of osteoporosis varied from 5.9 (Poland) to 7.2 % (Luxembourg). In women, the prevalence ranged from 19.1 (Cyprus) to 23.5 % (France).

The prevalence of osteoporosis in the entire EU27 population (i.e. all ages) was 5.5 % and ranged from 3.7 % in Cyprus and Ireland to 6.3 % in Italy (Fig. 3).

Score allocation

None—not a score card element

Comment

Although BMD is a strong predictor of fracture risk [10, 11], the prevalence of osteoporosis is not used as a score

Table 3 Estimated number of men and women with osteoporosis, prevalence in population over 50 years, and prevalence in the total population, 2010 [9]

Country	Men with osteoporosis	Women with osteoporosis	Men and women with osteoporosis	Prevalence in male population aged 50 or more (%)	Prevalence in female population aged 50 or more (%)	Prevalence in total population (%)
Austria	89,862	368,685	458,547	6.5	22.2	5.5
Belgium	120,695	476,875	597,570	6.6	22.4	5.6
Bulgaria	81,482	336,425	417,907	6.4	20.9	5.6
Cyprus	9,263	31,032	40,295	6.2	19.3	3.7
Czech Republic	103,114	425,944	529,058	6.0	20.4	5.0
Denmark	61,456	221,912	283,368	6.5	21.1	5.1
Estonia	11,642	65,789	77,431	6.2	22.2	5.8
Finland	61,054	243,399	304,453	6.4	21.5	5.7
France	691,112	2,784,198	3,475,310	6.7	22.5	5.5
Germany	1,006,652	4,017,260	5,023,912	6.6	22.6	6.1
Greece	135,202	507,505	642,707	6.9	22.3	5.7
Hungary	94,949	452,158	547,107	6.2	21.1	5.5
Ireland	37,127	129,309	166,436	6.2	20.0	3.7
Italy	749,237	3,042,794	3,792,031	6.9	23.4	6.3
Latvia	19,210	111,236	130,446	6.1	22.3	5.8
Lithuania	27,136	148,375	175,511	6.1	21.7	5.3
Luxembourg	4,541	17,422	21,963	6.1	21.0	4.3
Malta	4,190	16,074	20,264	5.9	19.8	4.9
Netherlands	175,244	643,258	818,502	6.3	20.8	4.9
Poland	338,756	1,509,772	1,848,528	5.8	20.1	4.8
Portugal	117,738	475,882	593,620	6.7	22.0	5.6
Romania	198,065	835,885	1,033,950	6.2	20.5	4.8
Slovakia	42,726	188,911	231,637	5.7	19.4	4.2
Slovenia	20,543	89,489	110,032	6.0	21.5	5.4
Spain	496,368	1,952,987	2,449,355	6.8	22.6	5.4
Sweden	113,722	409,373	523,095	6.9	22.4	5.6
UK	679,424	2,527,331	3,206,755	6.7	21.9	5.2
EU27	5,490,510	22,029,280	27,519,790	6.6	22.1	5.5




Fig. 3 Components (%) of the cost of osteoporosis and fractures [1]

card element because the relationship of osteoporosis to fracture risk varies by age and between countries [12]. For this reason, fracture risk is the preferred metric.

References

1. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC, Jr., Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. *Osteoporos Int* 8: 468–89
2. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, III, Khaltayev N (2008) A reference standard for the description of osteoporosis. *Bone* 42: 467–75
3. Gauthier A, Kanis JA, Jiang Y, Dreinhöfer K, Martin M, Compston J, Borgström F, Cooper C, McCloskey E (2012) Burden of postmenopausal osteoporosis in Germany: estimations from a disease model. *Arch Osteoporos* 7:209–18
4. Gauthier A, Kanis JA, Jiang Y, Martin M, Compston J, Borgström F, Cooper C, McCloskey E (2011) Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: Estimations from a Disease Model. *Arch Osteoporos* 6: 179–188
5. Gauthier A, Kanis JA, Martin M, Compston J, Borgström F, Cooper C, McCloskey E; Committee of Scientific Advisors, International Osteoporosis Foundation (2011) Development and validation of a disease model for postmenopausal osteoporosis. *Osteoporos Int* 22: 771–80
6. Cawston H, Maravic M, Fardellone P, Gauthier A, Kanis JA, Compston J, Borgström F, Cooper C, McCloskey E (2012) Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model. *Arch Osteoporos* 7: 237–46
7. Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jönsson B (2011) Osteoporosis; Burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos* 6:59–155
8. Odén A, McCloskey EV, Johansson H, Kanis JA (2013) The worldwide impact of osteoporosis on the burden of hip fractures. *Calcif Tiss Int* 92: 42–49
9. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos*, in press
10. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *Br Med J* 312: 1254–1259
11. Johnell O, Kanis JA, Oden A et al. (2005) Predictive value of bone mineral density for hip and other fractures. *J Bone Miner Res* 20:1185–1194
12. Kanis JA on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary healthcare level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK

1d Epidemiology of hip fracture

Domain

Burden of disease—scorecard element

Background and aims

Fracture incidence is poorly documented in the EU. The fracture incidence that has been best evaluated is hip fracture. Hip fractures account for the majority of health care expenditure, mortality and morbidity and can be used as a proxy for osteoporosis. There is a marked difference in the incidence of hip fracture worldwide and probably in other osteoporotic fractures [1]. Indeed, the difference in incidence between countries within Europe is greater than the differences in incidence between sexes within a country [2, 3]. The EU comprises countries with some of the highest hip fracture rates, but the documentation of the size of the problem and the quality of data vary between countries.

The aim of this scorecard element was to summarise the information base available for the incidence of hip fracture.

Methods

Studies on hip fracture risk were identified from 1950 to November 2011 by a Medline OVID search. Evaluable studies in each country were reviewed for quality and representativeness and a study (studies) chosen to represent that country. Age-specific incidence rates were age-standardised to the world population in 2010 in men and in women [1].

Results

National data on hip fracture rates were identified in 17 member states (Table 4). No data were available for four countries (Bulgaria, Cyprus, Latvia, and Luxembourg). In the remaining six countries, regional estimates were identified. For Estonia and Slovenia data were available in women only.

As expected, hip fracture rates were higher in women than in men with a female/male ratio that ranged from 1.4


Table 4 Information available on age-standardised (2010) hip fracture rates (/100,000/year) in countries of the European Union [1]

	Year	Sample	Incidence		F/M
			Women	Men	
Austria	2001–5	National	501	246	2.0
Belgium	2005–7	National	356	169	2.1
Bulgaria					
Cyprus					
Czech Republic	2008–9	National	374	211	1.8
Denmark	2004	National	574	290	2.0
Estonia	1991–4	Regional	225	–	–
Finland	2000–5	National	293	180	1.6
France	2004	National	291	126	2.3
Germany	2003–4	National	346	166	2.1
Greece	1986–92	Regional	326	158	2.1
Hungary	1999–03	National	367	206	1.8
Ireland	2008–10	National	406	191	2.1
Italy	2007	National	334	140	2.4
Latvia					
Lithuania	2010	National	270	156	1.7
Luxembourg					
Malta	2003–7	National	355	160	2.2
Netherlands	2005	National	249	121	2.1
Poland	2008	Regional	224	133	1.7
Portugal	2000–2	National	268	98	2.7
Romania	2005–9	National	198	142	1.4
Slovakia	2007	National	401	263	1.5
Slovenia	2003	National	349	–	–
Spain	1984–91	Regional	228	92	2.5
Sweden	1991	Regional	539	247	2.2
UK	1992–3	Regional	349	140	2.5

(Romania) to 2.7 (Portugal). There was a nearly three-fold range of hip fracture rates throughout the EU from 198/100,000 (Romania) to 574/100,000 (Denmark). Thus, the international variation between countries was greater than the differences between men and women within countries.

Table 5 Criteria for allocating scores

Annual hip fracture (rate/100,000)	Colour code	Criteria
<300	Green	Moderate risk
300–400	Orange	High risk
400+	Red	Very high risk
	Black	No data available

**Fig. 4** Annual incidence of hip fracture in women from countries of the EU age-standardised to the world population for 2010 [1]

Score criteria

The age-standardised incidence was ranked. Women were chosen since fracture rates are more robust and it permitted the inclusion of Estonia and Slovenia for which no data were available in men. The criteria for categorisation were chosen as described in Table 5.

Score allocation

The ranked incidence is shown in Fig. 4 and colour coded by category.

Comment

On an international scale, all countries were at moderate or high risk (150–250/100,000 and >250/100,000, respectively) [1].

Reasons for the large variation in fracture risk between countries are speculative, but, ecological studies have shown a weak but significant relationship between hip fracture risk and latitude and socio-economic prosperity [4].

References

1. Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl D, Cyrus Cooper C on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. *Osteoporos Int* 23: 2239–2256.
2. Johnell, O, Gullberg, B, Allender, A, Kanis, JA, and the MEDOS Study Group (1992) The apparent incidence of hip fracture in Europe. *Osteoporos Int* 2, 298–302.
3. Elffors L, Allander E, Kanis JA, Gullberg B, Johnell O, Dequeker J, Dilzen G, Gennari C, Lopez-Vaz AA, Lyritis G, Mazzuoli GF,

Miravet L, Passeri M, Perez Cano R, Rapado A, Ribot C (1994) The variable incidence of hip fracture in Southern Europe. The MEDOS Study. *Osteoporos Int* 4, 253–263.

4. Johnell O, Borgström F, Jonsson B, Kanis J (2007) Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. *Osteoporos Int* 18:333–337

1e Number of fragility fractures

Domain

Burden of disease—scorecard element

Background and aims

The most obvious and serious effect of osteoporosis is the fractures that occur as a consequence of increased bone fragility. This section determines the number of fractures associated with bone fragility in the EU27.

Methods

The fractures of interest include those at the hip, spine and forearm as well as osteoporotic fractures at other vulnerable sites (humerus, ribs, tibia, pelvis and other femoral fractures) grouped as other fractures. Information on the incidence of osteoporotic fractures varies between the countries of the EU27. In general, reports on hip fracture incidence are more complete than for fractures at other sites (see Chapter 1d).

The risk of hip fracture was taken from a systematic review of hip fracture incidence [1]. For the EU27 countries with incomplete information, incidence was taken from the nearest country where hip fracture incidence was available [2]. Where the incidence of fractures other than the hip was not available, the incidence was imputed from the hip fracture incidence in the relevant country, using the relationship between hip fracture incidence and incidence of fracture in other sites in Sweden [3].

The number of fractures in each country for each fracture site was computed from the age- and sex-specific estimates of incidence and population demography for 2010 [4]. Crude incidence in each country was expressed as the number of fragility fractures per 1000 of the population aged 50 years or more.

Results

There were estimated to be 3.5 million new fragility fractures in the EU in 2010—equivalent to 9,556 fractures/day (or

Table 6 Estimated number of incident fractures in the EU27 by site, 2010 [2]

	Men	Women	Men and women
Hip fractures	168,511	446,806	615,317
Vertebral fractures	188,867	327,397	516,264
Forearm fractures	96,307	464,273	560,580
Other fractures	740,590	1,059,307	1,799,897
All fractures	1,194,275	2,297,783	3,492,058

390/h) (Table 6). Almost twice as many fractures occurred in women compared to men. Hip, vertebral, forearm and other fractures accounted for 18, 15, 16 and 51 % of all fractures, respectively.

The number of incident fractures per country is shown in Table 7. Germany had the highest number of fractures for

Table 7 The number of new fragility fractures in 2010 in men and women by country, the population at risk (men and women aged 50 years or more) and the crude incidence (/1000 of the population) [2]

Country	New fractures	Population at risk (000)	Rate/1,000
Austria	86,536	3,041	28.5
Belgium	79,893	3,959	20.2
Bulgaria	38,198	2,876	13.3
Cyprus	5,129	311	16.5
Czech Republic	72,195	3,802	19.0
Denmark	66,358	2,003	33.1
Estonia	8,688	485	17.9
Finland	36,405	2,090	17.4
France	376,774	22,645	16.6
Germany	724,774	33,010	22.0
Greece	85,518	4,236	20.2
Hungary	102,457	3,683	27.8
Ireland	18,085	1,246	14.5
Italy	465,400	23,788	19.6
Latvia	14,305	812	17.6
Lithuania	15,074	1,127	13.4
Luxembourg	2700	158	17.1
Malta	2641	152	17.4
Netherlands	75,947	5,893	12.9
Poland	167,664	13,350	12.6
Portugal	51,821	3,922	13.2
Romania	94,282	7,289	12.9
Slovakia	38,634	1,730	22.3
Slovenia	15,510	759	20.4
Spain	204,151	15,905	12.8
Sweden	107,046	3,489	30.7
United Kingdom	535,873	21,636	24.8
EU27	3,492,058	183,397	19.0

Deaths (per 100,000 inhabitants aged 50+ years)




Fig. 5 The number of deaths associated with fracture events expressed per 100,000 of the population added 50 years or more in the EU27 [2]

all fracture types in both men and women—approximately 724 000 incident fractures in total—predominately reflecting a large population size and comparatively high fracture incidence. Malta and Luxembourg had the lowest number of fractures for all types—(less than 3 000 incident fractures in each country), reflecting small population sizes.

When fracture numbers were expressed as a rate of the population at risk, there was a greater than two-fold range in risk that varied from 12.6/1000 in Poland to 33.1/1000 in Denmark.

In addition to pain and disability, some osteoporotic fractures are associated with premature mortality. About 30 % of deaths after a hip or clinical spine fracture can be attributed to the fracture event [5–7]. In the EU, there were estimated to be 43,000 deaths causally related to in 2010. Approximately 50 % of fracture-related deaths in women were due to hip fractures, 28 % to clinical vertebral and 22 % to other fractures. Corresponding proportions for men were 47, 39 and 14 %, respectively. Fracture-related deaths by country are shown in Fig. 5. Note that the variability in death rates is more a reflection of the variable incidence of fractures rather than in standards of care.

Score criteria

The number of fragility fractures in men and women combined in 2010 expressed/1,000 of the population aged

Table 8 Criteria for allocating scores

Incidence		
<15/1000		Moderate risk
15-20/1000		High risk
>20/1000		Very high risk

Fractures/1000 of the population aged 50+ years




Fig. 6 The annual number of fragility fractures in men and women combined expressed/1,000 of the population aged 50 years or more

50 years or more was categorised approximately by tertiles as given in Table 8.

Score allocation

Countries, ranked and categorised by risk, are shown in Fig. 6. The variation between countries reflects both the fracture risk and the distribution of age and sex in each country.

Comment

The calculation of fracture numbers from hip fracture rates assumes that the ratios between age- and sex-specific incidence of hip fracture and fractures of other sites found in Sweden are similar in other countries. This assumption has been shown to hold true for the countries where this has been tested [3, 8].

These estimates do not include individuals who in 2010 were suffering the consequences of fractures sustained in previous years.

There are important data gaps in the documentation of the fracture burden between member states which form the component of a further scorecard element (Chapter 2a).

References

1. Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl D, Cyrus Cooper C on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. *Osteoporos Intl* 23: 2239–2256.
2. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in

collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos, in press

3. Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. *Osteoporos Int* 12: 417–27
4. UN (2010) Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat (2010) World Population Prospects: The 2010 Revision, <http://esa.un.org/unpd/wpp/index.htm> Accessed 16th December 2012
5. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. *Bone* 32: 468–473
6. Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Pettersson C, De Laet C, Jönsson B (2004) Mortality after osteoporotic fractures. *Osteoporos Int* 15: 38–42
7. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. *Osteoporos Int* 15:108–12.
8. Kanis JA, Hans D, Cooper C, et al. (2011) Interpretation and use of FRAX in clinical practice. *Osteoporos Int* 22: 395–411.

1f Lifetime hip fracture probability

Domain

Burden of disease—scorecard element

Background and aims

The most serious consequence of osteoporosis in terms of morbidity, mortality and health care expenditure is hip fracture. In the EU, for example, hip fractures comprise only 17 % of the total number of fragility fractures but account for 54 % of the direct costs and 49 % of deaths due to fracture [1]. The likelihood of hip fracture can be expressed as fracture probability from a given age over a given time interval (e.g. 10 years).

The aim of this element is to provide estimates of the remaining lifetime probability of hip fracture in men and women at the age of 50 and 70 years.

Methods

Hip fracture probability was computed taking both the risk of fracture and the risk of death into account [2]. The risk of hip fracture was taken from a systematic review of hip fracture incidence [3]. Where possible, the incidence of hip fracture was determined in men and women using 5-year age categories. Where 5-year age intervals were not available, 10 year intervals were used (intervals of greater than 10 years were an exclusion criterion). Mortality statistics of the WHO were used in 5 or 10 year age

intervals for the year 2010 [4]. The remaining lifetime probabilities were calculated in men and women from the age of 50 and 70 years.

Results

Empirical data on hip fracture rates were available for 21 of the 27 EU member states in men and women. No data were available for men from Estonia and Slovenia. Hip fracture incidence is not documented in Bulgaria, Cyprus, Latvia or Luxembourg.

The average remaining lifetime probability of hip fracture in women at the age of 50 years ranged from 7.0 % (Romania) to 25.1 % (Sweden). Thus, there was approximately a three-fold range of lifetime probabilities between countries (Table 9).

Table 9 Remaining lifetime probability of hip fracture (%) at the ages of 50 and 70 years in men and women by country, 2010 [3]

Country	Lifetime probability (%)			
	At age 50 years		At age 70 years	
	Men	Women	Men	Women
Austria	8.3	19.7	8.8	20.7
Belgium	7.8	18.2	8.3	18.9
Bulgaria	–	–	–	–
Cyprus	–	–	–	–
Czech Republic	6.9	14.8	7.5	15.6
Denmark	10.6	22.1	11.1	23.6
Estonia	–	23.3	–	21.1
Finland	5.8	12.4	6.1	12.8
France	5.6	18.4	6.3	19.4
Germany	5.3	14.2	5.6	15.0
Greece	8.0	15.8	8.6	15.2
Hungary	4.1	10.6	5.2	12.0
Ireland	7.8	18.2	8.0	18.7
Italy	7.7	19.2	7.8	19.3
Latvia	–	–	–	–
Lithuania	4.4	11.3	5.3	11.9
Luxembourg	–	–	–	–
Malta	5.8	14.2	5.8	14.2
Netherlands	5.4	12.5	5.6	12.8
Poland	4.0	9.7	3.9	10.1
Portugal	4.8	14.4	5.3	14.9
Romania	3.8	7.0	3.7	7.2
Slovakia	9.5	20.3	9.9	20.3
Slovenia	–	11.6	–	12.0
Spain	4.0	12.1	4.3	12.6
Sweden	10.9	25.1	11.0	25.4
United Kingdom	4.8	13.8	5.0	14.6

– denotes no data




Fig. 7 Remaining lifetime probability of hip fracture (%) in men and women from 21 countries in the EU from the age of 50 years [1]

Probabilities of hip fracture were approximately two-fold lower in men than in women. In men, hip fracture probability at the age of 50 years ranged from 3.8 % (Romania) to 10.9 % (Sweden). There was a close correlation between hip fracture probability in men and women so that in those countries where fracture probability was high in women, so too was it high in men (Fig. 7). In Sweden, which had the highest hip fracture probabilities, the hip fracture risk in men (10.9 %) was higher than the hip fracture probability in women from Hungary, Poland or Romania.

Score criteria

The remaining lifetime probability of hip fracture at the age of 50 years was ranked. Women were chosen since it

Table 10 Criteria for allocating scores

Lifetime probability (%) of hip fracture	Colour code	Criteria
<13	Green	Moderate probability
13-18	Orange	High probability
>18	Red	Very high probability
	Black	No data available




Fig. 8 Remaining lifetime probability of hip fracture (%) in women in the EU from the age of 50 years [1]

permitted the inclusion of Estonia and Slovenia for which no data were available in men. The criteria for categorisation are shown in Table 10.

Score allocation

The ranked incidence is shown in Fig. 8 and colour coded by category.

Comment

Hip fracture probabilities from the age of 70 years were not markedly different from those from the age of 50 years. The reason for this is that increasing death and fracture hazards with age compete in the determination of probability.

References

- Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos, in press
- Kanis JA, Johnell O, Oden A, Johansson H, McCloskey EV (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19: 385–397.
- Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl D, Cooper C on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23: 2239–2256.
- United Nations (2010) World Population prospects, the 2010 revision. Department of Economic and Social Affairs, UN (http://esa.un.org/unpd/wpp/unpp/panel_indicators.htm) accessed 2nd November 2011

1g Men and women at high fracture risk

Domain

Burden of disease—scorecard element

Background and aims

The advent of FRAX in 2008 [1] provided a clinical tool for the calculation of fracture probability. Probability-based assessment is increasingly being incorporated into clinical guidelines in Europe [2, 3] and elsewhere. Unlike fracture incidence, the probability of fracture at any given age depends upon the hazard of death as well as the hazard of fracture over a defined interval (e.g., 10 years or lifetime). A major advantage of using fracture probability is that it standardises the output from the multiple techniques and sites used for assessment and also permits the presence or absence of risk factors other than BMD to be incorporated as a single metric. FRAX models are also calibrated to country-specific epidemiology.

The ability to compute fracture probabilities in individuals permits an estimate of the prevalence of high risk individuals within a given population where the population demography and the distribution of FRAX-based probabilities are known.

The aim of this score card element was to present the burden of osteoporosis in men and women in the EU27 countries expressed as the proportion of the population that has a 10 year probability of a major fracture (hip, spine, forearm or humerus) above a given threshold.

Methods

There is no international standard for defining high risk based on probabilities. In Europe, intervention thresholds are commonly defined as the 10-year probability of a major fracture that equals or exceeds that of a woman with a prior fragility fracture [2, 3], termed the probability fracture threshold. In North America threshold risks have been set at probabilities of 10 and 20 % [4, 5] and these were used for this assessment.

The majority of EU member states have a country-specific FRAX model. Where unavailable, a surrogate model was used. The distribution of FRAX probabilities in men and women was simulated in 5-year age intervals for each member state between the ages of 50 to 89 years [6] and applied to the demography of each country for 2010 [7]. Burden of disease was expressed as the number of men and women with a probability of major fracture above a threshold of 10 or 20 %. For comparative purposes, the burden was

expressed as the proportion of the population aged 50–89 years with probabilities above these thresholds.

Results

Approximately 12.9 million men and women in the EU27 have a 10-year fracture probability that is 20 % or more. When a 10 % threshold is used the population at high risk rises to 41.3 million, representing respectively 3 and 8 % of the total EU population for 2010.

The proportion of the population aged 50 years or more that in 2010 had a fracture probability of 20 % or more varied among member EU states, ranging from 2 % in Romania to 17 % in Sweden (Table 11). The proportion of

Table 11 Number of men and women (000) and proportion of the population aged 50–89 years (%) with a 10-year probability of a major fracture that exceeds 10 %, 20 % or the fracture threshold for women

Country	Number of men and women (000)			Proportion of population aged 50–89 years (%)		
	>20 %	>10 %	>Fracture threshold	>20 %	>10 %	>Fracture threshold
Austria	407	1,101	325	14	37	11
Belgium	355	1,058	460	9	27	12
Bulgaria	51	308	330	2	11	12
Cyprus	20	68	36	6	22	12
Czech	293	926	431	8	25	11
Denmark	377	937	214	19	48	11
Estonia	24	92	60	5	19	13
Finland	109	402	222	5	20	11
France	1,667	4,638	2,717	8	21	12
Germany	2,434	7,840	3,773	7	24	12
Greece	333	1,110	524	8	27	13
Hungary	238	842	393	7	23	11
Ireland	110	339	141	9	28	11
Italy	2,093	6,592	2,864	9	28	12
Latvia	39	155	102	5	19	13
Lithuania	53	209	141	5	19	13
Luxembourg	13	39	18	8	25	12
Malta	10	35	18	7	23	12
Netherlands	221	881	681	4	15	12
Poland	375	1,567	1,540	3	12	12
Portugal	200	656	479	5	17	12
Romania	127	761	834	2	10	12
Slovakia	139	527	197	8	31	11
Slovenia	49	169	78	6	23	10
Spain	664	2,284	1,947	4	15	12
Sweden	567	1,437	398	17	42	12
UK	1,947	6,310	2,416	9	30	11
EU27	12,915	41,283	21,339			




Fig. 9 Proportion of men and women (%) aged 50–89 years with a 10-year probability of a major fracture that is 10 % or more and 20 % or more by member state

the population aged 50 years or more that had a fracture probability of 10 % or more ranged from 12 % in Romania to 42 % in Sweden (Table 11). Figure 9 shows the rank order of population burden.

For completion, the table also shows the number of men and women that lie above a fracture threshold commonly used in assessment guidelines. This is considered later in relationship to the uptake of treatments in the EU27 (Chapter 4c).

Score criteria

Countries were ranked by tertiles of prevalence of the population aged 50–89 years above a 10 % probability threshold of a major osteoporotic fracture as given in Table 12.

Score allocation

The proportion of the population (%) aged 50–89 years with a 10-year probability of a major fracture that is 10 % or more by member state is shown by category and rank in Fig. 10.

Table 12 Criteria for allocating scores

<20% of the population		Moderate risk
20–25% of the population		High risk
>25% of the population		Very high risk




Fig. 10 The proportion of the population (%) aged 50–89 years with a 10-year probability of a major fracture that is 10 % or more by member state

Comment

The majority of EU member states have a country-specific FRAX model. For those countries where a country-specific FRAX model was unavailable, a surrogate model was used, based on the estimate that the epidemiology of hip fracture was similar. For Bulgaria, the Romanian model was used; for Cyprus, the Maltese model was used; for Estonia and Latvia, the Lithuanian model was used; for Luxembourg, the Belgian model was used; and for Slovenia, the Hungarian model was used.

References

1. Kanis JA on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. Accessed http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf
2. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 24: 23–57
3. Lekawasam S, Adachi JD, Agnusdei D et al. for the Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporos Int* 23:2257–76.
4. Dawson-Hughes B, Looker AC, Tosteson ANA, Johansson H, Kanis JA, Melton III LJ (2010) The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. *Osteoporos Int* 21: 41–52
5. Papaioannou A, Morin S, Cheung AM et al. (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *CMAJ* 182: 1864–73

6. Kanis JA, Johansson H, Odén A, McCloskey EV (2012) The distribution of FRAX® based probabilities in women from Japan. *J Bone Miner Metab* 30:700–5
7. UN (2010) Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat (2010) World Population Prospects: The 2010 Revision, <http://esa.un.org/unpd/wpp/index.htm> Accessed 16th December 2012

1h Population projections

Domain

Burden of disease—background information

Background and aims

Secular changes in life expectancy and birth rate are likely to increase the number of elderly individuals in the EU member states and thereby increase the need for resource allocation for diseases associated with ageing. The incidence of fragility fractures increases markedly with age, particularly in women. The aim of this background element is to estimate the increase in number of women aged 50 years or more in the EU member states.

Methods

The age and sex distribution of the EU member states was obtained from the UN for 2010 and 2025 using the medium variant [1].

Results

The population of women over 50 years is expected to increase by 22 % and in men by 17 % in the EU between 2010 and 2025. The number of men and women aged 50 years or more will increase in all countries except Bulgaria, Hungary and Latvia (Table 13). In the remaining countries, the increment in the population varies widely.

With some exceptions, the percentage increase in number of men and women aged 75 or more years is greater than that of the population aged 50–74 years. The exceptions include Belgium (women), Bulgaria (men), Greece (men), Lithuania (men), Luxembourg (women), Romania (men) and Spain (men and women).

For women over the age of 75 years, the change in the population ranged from less than 10 % in Latvia (7 %) and Lithuania (9 %) to more than 40 % in Cyprus, Denmark, Finland, Ireland, Malta and the Netherlands (Fig. 11).

Table 13 Projected percentage change in the male and female population between 2010 and 2025 according to category of age [1]

Country	Men aged		Women aged	
	50–74 years	75+ years	50–74 years	75+ years
Austria	25	57	22	26
Belgium	18	27	17	13
Bulgaria	−1	−1	−3	11
Cyprus	36	57	31	63
Czech Republic	9	57	4	37
Denmark	10	70	10	45
Estonia	6	21	0	14
Finland	2	81	1	41
France	17	40	17	22
Germany	13	52	10	23
Greece	23	18	17	18
Hungary	6	19	−1	18
Ireland	37	73	38	53
Italy	25	35	18	21
Latvia	8	13	−2	7
Lithuania	12	3	6	9
Luxembourg	36	64	43	25
Malta	6	100	5	50
Netherlands	19	75	19	41
Poland	8	24	7	21
Portugal	22	31	17	25
Romania	14	6	10	19
Slovakia	22	38	16	32
Slovenia	18	60	15	25
Spain	42	33	35	22
Sweden	10	61	9	35
UK	17	46	17	29




Fig. 11 Projected increase by country in the female population aged 75 years or more (%) between 2010 and 2025 [1]




Fig. 12 The relation between the percentage increase in the male and female population aged 75 years or more in EU member states. The diagonal shows the line of identity

The increase in the male population aged over 75 years was generally more marked than in women. In men, the EU population aged 75 years or more is expected to increase by 33 %. In those countries with large expected changes in the proportion of the population aged 75 years or more, the increment is larger in men than in women (Fig. 12) since life expectancy, lower in men, is improving more rapidly in men than in women with time.

Score criteria

None—not a score card element

Comment

UN population projections over 15 years are relatively robust in that all men and women in 2025 aged 50 years or more had already attained adulthood in 2010. The projections expressed in relative change for countries with very small populations are uncertain (e.g. Malta, Cyprus) since population numbers are given by the UN rounded to the nearest 1000.

References

1. United Nations (2010) Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, World Population Prospects: http://esa.un.org/unpd/wpp/unpp/panel_indicators.htm, accessed May2012;

1i Fracture projections

Domain

Burden of disease—scorecard element

Background and aims

As noted, the number of men and women aged 50 years or more is set to increase with time in the EU. The increase will be particularly marked in the elderly population. Since age is an important risk factor for fractures and the elderly population is projected to increase in the majority of member countries, the burden of fractures is also likely to increase.

Table 14 Number of fractures in men and women in 2010 and number expected in 2025, and the percentage increase [2]

Country	Number of fractures 2010	Number of fractures 2025	Δ fractures 2010–2025 (number)	Δ fractures 2010–2025 (%)	Share of EU27 increase
Austria	86,031	115,686	29,655	34	3
Belgium	79,201	98,525	19,324	24	2
Bulgaria	38,184	39,612	1,429	4	0
Cyprus	5,022	7,536	2,514	50	0
Czech Republic	75,359	97,829	22,470	30	2
Denmark	66,066	86,094	20,028	30	2
Estonia	8,678	10,208	1,530	18	0
Finland	36,292	48,939	12,647	35	1
France	378,082	493,031	114,949	30	12
Germany	732,137	936,461	204,324	28	21
Greece	84,256	105,284	21,028	25	2
Hungary	90,011	101,544	11,533	13	1
Ireland	17,947	27,372	9,425	53	1
Italy	466,475	599,034	132,559	28	13
Latvia	14,284	16,204	1,920	13	0
Lithuania	15,084	17,484	2,400	16	0
Luxembourg	2,684	4,015	1,331	50	0
Malta	2,618	3,744	1,125	43	0
Netherlands	76,691	107,671	30,980	40	3
Poland	167,033	208,591	41,558	25	4
Portugal	51,329	68,448	17,119	33	2
Romania	94,240	110,099	15,858	17	2
Slovakia	38,363	49,508	11,145	29	1
Slovenia	15,471	21,795	6,323	41	1
Spain	203,794	285,453	81,659	40	8
Sweden	106,857	135,029	28,172	26	3
UK	535,724	681,956	146,231	27	15
EU27	3,487,914	4,477,152	989,238	28	100

The aim of this scorecard element was to estimate the increase in the annual number of fragility fractures from 2010 to 2025.

Methods

The incidence of hip fracture was determined from a systematic literature review [1, 2]. For other fractures, it was assumed that the age- and sex-specific incidence in relation to hip fracture followed that documented for Sweden [3] and other non-EU countries [4]. Outcomes included the three most common sites of osteoporotic fracture (hip, spine and forearm) as well as other fractures considered to be associated with osteoporosis (i.e. pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum, and lower femur) [3]. For vertebral fractures, only those coming to clinical attention were included.

Fracture numbers were calculated from age- and sex-specific incidence and population sizes in 5-year age intervals for 2010 and 2025 [5]. It was assumed that the incidence of osteoporotic fractures did not change over time.

Results

The annual number of osteoporotic fractures in the EU27 will increase by 0.99 million from 3.49 million in 2010 to 4.48 million in 2025 (Table 14). The increase in the annual number of fractures is found in all countries (Fig. 13), ranging from a 53 % increase in Ireland to a modest 4 % increase in Bulgaria.




Fig. 13 The percentage increase in the number of fragility fractures between 2010 and 2025 in the EU and its member states [2]

Table 15 Criteria for allocating scores

0-25% increase	Moderate increase	
26-33% increase	Large increase	
>33% increase	Very large increase	

Score criteria

Countries were ranked by the percentage increase in the annual number of fractures in men and women between 2010 and 2025 as shown in Table 15.

Score allocation

The percentage increase in the annual number of fractures in men and women between 2010 and 2025 is shown by category and rank in Fig. 13.

Comment

The analysis assumes that the age- and sex-specific incidence of fractures did not change over the 15-year time interval. Secular trends in fracture risk are ill-documented with the exception of hip fracture [6] where limited information is available. In general, age- and sex-adjusted hip fracture incidence increased until the mid or end of the 20th century, with a subsequent plateau or even a small decrease [6]. In Europe, this tendency is best documented for Sweden, Finland, Spain, Germany, Netherlands and Hungary.

Countries with substantial increases in the number of fractures need to take this into account for future healthcare planning.

References

1. Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl D, Cyrus Cooper C on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. *Osteoporosis International* 23: 2239–2256.
2. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos*, in press

3. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. *Osteoporos Int* 12: 417–427.
4. Kanis JA, Hans D, Cooper C et al. (2011) Interpretation and use of FRAX in clinical practice. *Osteoporos Int* 22: 395–411.
5. United Nations (2010) Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, World Population Prospects: http://esa.un.org/unpd/wpp/unpp/panel_indicators.htm, accessed May2012.
6. Cooper C, Cole ZA, Holroyd CR et al. (2011) Secular trends in the incidence of hip and other osteoporotic fractures. *Osteoporos Int* 22: 1277–1288.

Chapter 2 Policy framework

2a Quality of existing information

Domain

Policy framework—scorecard element

Background and aims

Fracture incidence is poorly documented in the EU [1]. The fracture that has been best evaluated is hip fracture. Hip fractures account for the majority of health care expenditure, mortality and morbidity and can be used as a proxy for osteoporosis. The EU comprises countries with some of the highest hip fracture rates worldwide [2], but documentation of the size of the problem and the quality of data vary between countries.

Documentation of the burden of disease is an essential prerequisite to determine the resources that should be allocated to the diagnosis and treatment of the disorder. It also provides information concerning the priority a disease should be awarded by healthcare policy makers. A fracture registry is a centralised database collecting the number of individual fractures per person, per year within a population and is used for research and resource allocation. The data collected can also be used to identify high-risk patients in need of further prevention programs. The main objective of this scorecard element is to provide an integrated estimate of the quality of current documentation on the burden of osteoporosis fractures in the countries of the European Union.

Methods

Published information on hip fracture incidence was obtained by systematic review, in some cases through contact with Ministries of Health [2]. Available studies in each country were reviewed for quality and representativeness of the country. Epidemiology of other fractures was obtained by systematic review [1].

Data on national or regional fracture registers [3] were updated by an IOF questionnaire to the EU Osteoporosis Consultation Panel.

The quality of the available information was scored, with the presence of an established national fracture register as the highest grade. In the absence of a fracture register, an intermediate score was dependent on the presence of good quality national hip fracture rates.

Results

High quality national data on hip fracture rates were identified in 15 member states (Table 16). Fair to poor quality national estimates were found for Lithuania and Slovenia. No data were available for four countries (Bulgaria, Cyprus, Latvia, and Luxembourg). In the remaining six countries, regional estimates of variable quality were identified. Most index years included data from 2000 onwards.

Data on the incidence of clinical vertebral fractures are lacking in most of the countries in the EU, the exceptions being regional data for Sweden and the UK. In the UK, the incidence of clinically identified fractures has been studied within the General Practice Research Database (GPRD). The incidence is, however, very low and it is likely that the majority of fractures were not coded.

Information on forearm fracture is also scarce. Forearm fractures are treated in hospital outpatient departments. There are reports from EU27 countries on the incidence of forearm fractures that lead to hospitalisation, e.g. from France and Italy, but these are of limited value. There are also studies published from Slovenia and Italy which present incidence of forearm fractures treated both in inpatient and outpatient care. However, the Slovenian study only reports fractures occurring in women, and the Italian study lacks age stratification of data within the elderly population. Credible data are only available for Hungary, the UK and Sweden [1].

National fracture registries were in place in 12 of the EU countries (Table 16). The majority of these acquire information on all or several fracture outcomes (Austria, Denmark, Finland, Germany, Hungary, Ireland, Latvia, Netherlands, Portugal and Slovakia) and the remainder registered hip fracture alone (Belgium, Ireland, Sweden and UK). In several additional countries, local registers are available.

Score criteria

The presence of an established national fracture register was allocated the highest grade. In the absence of a fracture register, an intermediate score was given with the availability of good quality national hip fracture rates. Criteria for allocating scores are given in Table 17.

Score allocation

Countries, ranked and categorised by score, are shown in Fig. 14.

Table 16 Characteristics of information available on fracture rates in the European Union

	Incidence of hip fracture		Established National Fracture Registries		Score
	Quality ^a	Sample ^b	Present	Data ^c	
Austria	G	N	No ^d		3
Belgium	G	N	Yes	Hip	3
Bulgaria			No		0
Cyprus			No		0
Czech Republic	G	N	No		2
Denmark	G	N	Yes	Hip+	3
Estonia	P	R	No		1
Finland	G	N	Yes	Hip+	3
France	G	N	No ^d		2
Germany	G	N	Yes	Hip+	3
Greece	P/F/G	R	No		1
Hungary	G	N	Yes	Hip+	3
Ireland	G	N	Yes	Hip	3
Italy	G	N	No ^d	Hip+	2
Latvia		R	Yes	Hip+	3
Lithuania	F	R	No		1
Luxembourg			No		0
Malta	G	N	No		2
Netherlands	G	N	Yes	Hip+	3
Poland	F	R	No		1
Portugal	G	N	Yes	Hip+	3
Romania	G	N	No		2
Slovakia	G	N	Yes	Hip+	3
Slovenia	F	N	No		2
Spain	F/G	R	No ^d	Hip+	1
Sweden	G	R	Yes	Hip	3
UK	G	R	Yes	Hip	3

Responses derived from questionnaire to National Societies

^a Quality: *G* good; *F* fair; *P* poor [2]


^b Catchment: *N* national; *R* regional

^c *Hip* Registration of hip fracture only. *Hip+* Registration of hip and other fracture outcomes

^d Regional registers available

Table 17 Criteria for allocating scores

Score	Colour code	Criteria
3	Green	Established national hip fracture registries.
2	Orange	Good quality national hip fracture rates
1	Red	Poor quality national data or regional data only
0	Black	No data available

**Fig. 14** Quality of information available on the epidemiology of hip fractures in the EU [IOF audit]

Comments

The quality of this information is limited. Firstly, it is based on responses to a questionnaire to national societies and not to government agencies. Secondly, centralised data are not necessarily equivalent to a national registry.

References

1. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos, in press
2. Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl D, Cyrus Cooper C on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int23: 2239–2256
3. International Osteoporosis Foundation (2008) Osteoporosis in the European Union in 2008: Ten years of progress and ongoing challenges. IOF, Nyon. Available at www.iofbonehealth.org accessed 23rd Sept 2012

2b National health priority

Domain

Policy framework—scorecard element

Background and aims

Data from the Global Burden of Disease 2010 Study indicate that musculoskeletal disorders are the second greatest cause of disability as measured by years lived with

Table 18 Countries in which osteoporosis or musculoskeletal diseases were officially documented as a NHP, its scope and action plans

	NHP and date	Government support	Scope ^a	Action plan	Score
Austria	No		–		1
Belgium	No		–		1
Bulgaria	Yes 2006	Yes	N, FLS	Yes	3
Cyprus	No				1
Czech Republic	No				1
Denmark	No				1
Estonia	No				1
Finland	Yes	Yes	N, E, F	No	2
France	Yes 2004	Yes	N, E, F	No	2
Germany	No				1
Greece	No				1
Hungary	No		–		1
Ireland	No				1
Italy	Yes 2005	Yes	N, F	Uncertain	2
Latvia	No				1
Lithuania	No				1
Luxembourg	Yes	Yes	N, E, F	Yes	3
Malta	No				1
Netherlands	No				1
Poland	No				1
Portugal	Yes 2004	Yes	P	Rarely implemented	2
Romania	Yes	Yes	Case finding	Yes	3
Slovakia	No				1
Slovenia	No				1
Spain	No				1
Sweden	Yes 2012	Yes	Not yet defined	No	2
UK	Yes 2009	Yes	NE, FLS	Indirect	3

Responses derived from questionnaire to National Societies

^aN, E, F Nutrition, Exercise, Falls prevention; P professional education; FLS Fracture liaison services

disability (YLD), worldwide and across most regions of the world [1]. In terms of both death and disability, musculoskeletal diseases are the non-communicable diseases that have the fourth greatest impact on the health of the world population (6.8 %). They closely follow cardiovascular and circulatory diseases (11.8 %), tumours (7.7 %), and mental/behavioural disorders (7.4 %) [2]. Disability due to musculoskeletal disorders has increased by 45 % from 1990 to 2010 compared to a 33 % average across all other disease areas. These data suggest that musculoskeletal disease merits a high priority in health care policy. Osteoporotic


fractures in Europe accounted for more disability-adjusted life years lost (2,006,000 DALYs) than rheumatoid arthritis (1,048,000) but less than that for osteoarthritis (3,088,000) representing 33 % of the DALYs of these disorders [3].

When a disease becomes a National Health Priority (NHP), it is usually mandated by a government body/ministry of health or another official institution. Osteoporosis may be a designated NHP on its own, or it may be included as part of a musculoskeletal diseases NHP. The development of a national action plan, clear objectives

Table 19 Criteria for allocating scores

3		National Health Priority (NHP) and its implementation
2		NHP but little or no implementation
1		No NHP

Fig. 15 Categorisation of EU countries according to the existence of government-backed NHP for osteoporosis or musculoskeletal diseases [IOF audit]



and support for education and awareness programs also often result from a NHP mandate. The aim of this scorecard element was to determine the extent to which member states have recognised this need.

Methods

Information on NHP [4] was updated by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012.

Respondents were asked whether osteoporosis or musculoskeletal diseases were officially documented as a NHP in each member state and to provide the documentary evidence. Further questions related to action plans linked to the NHP and their implementation.

Results

The majority of member states (18/27) do not recognise osteoporosis or musculoskeletal diseases as a NHP (Table 18). Of those member states that have developed a NHP, the focus has been on nutrition (six countries), falls prevention (four countries), exercise (four countries), and the institution of fracture liaison services (two countries). Action plans have been implemented in Bulgaria, Luxembourg and Romania. There is scant evidence for the implementation of action plans in Finland, France, Italy and Portugal. In Sweden, osteoporosis has only recently become a NFP (2012). In the UK, implementation is indirect via the establishment of

quality indicators in the audit of primary care practice (see Chapter 3h).

Score criteria

The presence of government-backed NHP with an implemented action plan was allocated the highest grade. In the absence of an action plan, an intermediate score was given. Criteria for allocating scores are given in Table 19.

Score allocation

Countries, ranked and categorised by score, are shown in Fig. 15.

Comment

Unless osteoporosis prevention and treatment become a priority for governments and health care providers, the growing number of osteoporotic fractures will have a serious impact on society—not just in terms of people's quality of life, but also because of increased costs incurred for acute healthcare, rehabilitation and nursing care.

References

- Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al. (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380: 2163–96

2. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C et al. (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 380:2197–2223.
3. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int* 17:1726–1733
4. International Osteoporosis Foundation (2008) Osteoporosis in the European Union in 2008: Ten years of progress and ongoing challenges. IOF, Nyon. Available at www.iofbonehealth.org accessed 23rd Sept 2012

2c Who manages osteoporosis?

Domain

Policy framework—scorecard element

Background and aims

In 2010, it is estimated that 22 million women and 5.5 million men in the EU had osteoporosis using the diagnostic criterion of the WHO [1]. In 2010, the number of new osteoporosis-related fractures in the EU was estimated at 3.5 million, comprising approximately 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures (i.e. pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum, and other femoral fractures). Osteoporosis is a common disease and effective treatments are widely available. As such, in most health care systems the vast majority of patients with osteoporosis is preferably managed at the primary health care level by general practitioners with specialist referral reserved for difficult cases, for example men and individuals in whom a secondary cause of osteoporosis is suspected.

The aim of this element was to determine whether the care of osteoporosis was primarily devolved to primary care physicians (GPs, family doctors). If not, then the lead specialty was asked for. The training of specialists is considered in Chapter 2d.

Methods

Data were acquired by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012. Respondents were asked whether osteoporosis was primarily devolved to primary care physicians (GPs, family doctors). If not, the single specialty that looked after most cases of osteoporosis was asked. In the case where there

Table 20 Care pathway for patients with osteoporosis by country

	Primarily devolved to primary care	Lead specialty	Score
Austria	yes		3
Belgium	yes		3
Bulgaria	no	Rheumatology, endocrinology	1
Cyprus	yes		3
Czech Republic	no	Clinical osteology, endocrinology	1
Denmark	no	Rheumatology, endocrinology	1
Estonia	yes		3
Finland	yes		3
France	yes		3
Germany	no	Orthopaedics, clinical osteology	
Greece	no	Orthopaedics	2
Hungary	no	Rheumatology	2
Ireland	no	Rheumatology, endocrinology, geriatrics	1
Italy	no	Rheumatology, endocrinology	1
Latvia	yes		3
Lithuania	yes		3
Luxembourg	yes		3
Malta	no	Rheumatology, gynaecology, endocrinology, geriatrics	1
Netherlands	yes		3
Poland	no	Rheumatology, orthopaedics, rehabilitation medicine, internal medicine	1
Portugal	yes		3
Romania	no	Rheumatology, endocrinology	1
Slovakia	no	Rheumatology, orthopaedics, endocrinology	1
Slovenia	yes		3
Spain	yes		3
Sweden	yes	Rheumatology, orthopaedics, endocrinology, internal medicine, geriatrics	3
UK	yes		3

Responses derived from questionnaire to National Societies

Table 21 Criteria for allocating scores

3		Osteoporosis mainly managed in primary care
2		Osteoporosis mainly managed by a single specialty
1		Osteoporosis mainly managed by a multiple specialties

was near equality between two or more specialties, they were each recorded.

Results

Primary care was the principal provider of the medical care of osteoporosis in 15 of the 27 EU member states (Table 20). In the remainder, the principal care was provided by hospital specialists. In Greece and Hungary, a single hospital specialty was the dominant provider (orthopaedics and rheumatology, respectively). In the remaining countries, the care of osteoporosis was split between disciplines. The number of disciplines was usually two (Bulgaria, Czech Republic, Denmark, Germany, Italy and Romania) but was three in the case of Ireland and Slovakia, and four or more for Malta, Poland and Sweden. The specialties involved comprised rheumatology (noted 10 times), endocrinology (9), orthopaedics (5), geriatrics (3), clinical osteology (2), internal medicine (2) gynaecology (1) and rehabilitation medicine (1). The panel were concerned by the multiplicity of specialists that had a primary role in the care pathway of patients in some countries and viewed this as an impediment to consistent care.

Score criteria

Where the care of osteoporosis was primarily devolved to primary care physicians (GPs, family doctors), this was allocated the highest grade. If not, then an intermediate score was given where osteoporosis is mainly managed by a single specialty, as given in Table 21.


Score allocation

Countries, ranked and categorised by score, are shown in Fig. 16.

Comment

Care management pathways are not necessarily divided by primary care and specialty care. The panel supports the view that long-term management should preferably be undertaken by GPs, contingent on adequate training, but there is a specialist role in initial evaluation, particularly in the context of fracture liaison services (see Chapter 3g). In

Fig. 16 Patterns of principal care of patients with osteoporosis [IOF audit]. *See comment below



Germany, there is the opportunity for specialists in many disciplines to be specially trained and accredited in the primary care of patients with osteoporosis. These considerations should temper the interpretation of the scores allocated.

Reference

1. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos, in press

2d Is osteoporosis a component of specialty training?

Domain

Policy framework—scorecard element

Background and aims

The large number of men and women who suffer the consequences of osteoporosis raises the question of whether there is adequate training of medical practitioners in this specialty and, indeed, which specialty takes a leadership role.

The aim of this background element was to determine whether osteoporosis and metabolic bone disease are a recognised specialty or recognised component of specialty training.

Methods

Data were acquired by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012. Information requested included whether osteoporosis or metabolic bone disease is a recognised medical specialty in each country. Also asked was whether osteoporosis or metabolic bone disease is a recognised component of specialty medical training and, finally, which specialists took lead roles in the care of osteoporosis.

The available information was scored, with the presence of an established specialty as the highest grade. In the absence of osteoporosis or metabolic bone disease being a recognised medical specialty, an intermediate score was

dependent on the disorder being a recognised component of specialty medical training.

Results

Osteoporosis and metabolic bone disease is a recognised specialty in only four of the EU member states (Czech Republic, Denmark, Estonia and Lithuania). In some countries, there are specialists that deal exclusively with metabolic bone diseases (e.g. the UK) most usually in an academic setting. The more usual finding is that the specialty care of osteoporosis is via another specialty (Table 22). The specialties involved include endocrinology, geriatrics, gynaecology, internal medicine, orthopaedic surgery, rehabilitation medicine and rheumatology. In the majority of countries, osteoporosis or metabolic bone disease is a recognised component of specialty medical training but there is no information on the extent to which this is taken advantage of. In Germany, a postgraduate training in clinical osteology is available to specialists from different disciplines to become certified. In two countries (Ireland and Poland) osteoporosis was neither an accepted medical specialty nor a component of specialty medical training. In the UK, experience in metabolic bone disease may form a component of specialist training but is not mandatory.

With the exception of Slovakia, the lead specialties are multiple. In some countries, all seven specialties took what were considered lead roles in the management of osteoporosis. This clearly indicates that there is no dominant specialty that looks after osteoporosis in any one country and a great diversity between countries. The specialty representation is illustrated in Fig. 17.

Score criteria

The highest score was allocated to a country if osteoporosis or metabolic bone disease was an established specialty. In the absence of osteoporosis or metabolic bone disease being a recognised medical specialty, an intermediate score was dependent on the disorder being recognised component of specialty medical training (Table 23).

Score allocation

The score allocation and grade for each country is shown in Fig. 18.

Table 22 Specialists caring for osteoporosis (OP)

	OP recognised as a specialty	Lead specialists ^a	OP recognised as a component of specialty training	Score
Austria	No	Rh, Orth, Gyn, Endo, Int	Yes	2
Belgium	No	Rh, Gyn, Endo, Ger, Rehab, Int	Yes	2
Bulgaria	No	Orth, Gyn, Int	Yes	2
Cyprus	No	Rh, Orth, Gyn, Endo, Int	Yes	2
Czech Republic	Yes	Rh, Orth, Gyn, Endo, Int	Yes	3
Denmark	Yes	Ger	Yes	3
Estonia	Yes	Orth, Endo, Rh	Yes	3
Finland	No	Rh, Orth, Gyn, Endo, Ger, Rehab, Int	Yes	2
France	No	Rh, Gyn, Endo, Ger	Yes	2
Germany	No	Rh, Orth, Gyn, Endo, Ger, Rehab, Int	Yes	2
Greece	No	Rh, Gyn, Endo	Yes	2
Hungary	No	Rh, Orth, Gyn, Endo, Rehab, Int	Yes	2
Ireland	No	Rh, Gyn, Endo, Ger, Rehab	No	1
Italy	No	Rh, Endo, Ger, Rehab, Int	Yes	2
Latvia	No	Rh, Endo, Int	Yes	2
Lithuania	Yes	Rh, Orth, Endo, Ger, Rehab, Int	Yes	3
Luxembourg	No	Rh, Orth, Gyn, Endo, Ger, Rehab, Int	Yes	2
Malta	No	Rh Orth, Gyn, Endo, Rehab, Int	Yes	2
Netherlands	No	Rh, Orth, Endo, Ger, Int	Yes	2
Poland	No	Rh, Orth, Endo,	No	1
Portugal	No	Rh, Orth, Gyn, Endo, Ger, Rehab	Yes	2
Romania	No	Orth, Rehab	Yes	2
Slovakia	No	Gyn	Yes	2
Slovenia	No	Rh, Gyn, Endo, Rehab	Yes	2
Spain	No	Rh, Orth, Gyn, Endo, Ger, Rehab, Int	Yes	2
Sweden	No	Rh, Orth, Endo, Int	Yes	2
UK	No	Rh, Orth, Endo, Ger, Gyn	Yes	2

Responses derived from questionnaire to National Societies

^aEndo endocrinology, Ger geriatrics, Gyn gynaecology, Int internal medicine, Orth orthopaedic surgery, Rehab rehabilitation medicine, Rh rheumatology


Fig. 17 The specialty representation in the EU countries. Note that more than one specialty per country can be represented (see Table 22) [IOF audit]

Table 23 Criteria for allocating scores

3	Osteoporosis or metabolic bone disease is a recognised specialty
2	Osteoporosis or metabolic bone disease is a recognised component of specialty medical training
1	Osteoporosis or metabolic bone disease is not a recognised specialty or component of specialty medical training

Comment

There is a wide variation in the specialties which cater for osteoporosis. Although it is possible that these specialties educate their trainees adequately, the wide variation may be reflected in inconsistent patient care, training of primary care physicians and a suboptimal voice to “defend” the interests of osteoporosis.

2e National Societies


Domain

Policy framework—scorecard element

Background and aims

The role of national patient societies is to improve the care of patients and increase awareness and prevention of osteoporosis and related fractures among the general public. In addition to their role in patient and public outreach, the societies provide practical and unbiased information for osteoporosis patients and their families through telephone help lines, local self-help groups and information events,

Specialist training score

**Fig. 18** The score allocation and grade for specialist training in each country [IOF]

media outreach, general educational activities and by distributing information via brochures and their websites. The patient societies often work closely with clinical and research associations to disseminate information about new treatments and patient guidelines. Finally, with their often large and active membership base, societies play an important role in advocacy by calling for access to timely and affordable diagnosis and treatment. This is particularly necessary for osteoporosis which, as a chronic ‘silent’ disease, is too often neglected by health authorities.

Methods

Data were acquired from the International Osteoporosis Foundation on the patient-contact societies operating in the European Union. Support societies fall into three categories: those primarily involved with direct patient contact (e.g. a

Table 24 The number and type of osteoporosis societies in the EU member states [IOF Audit]

	Patient contact	Patient orientated	Scientific	Score
Austria	1	1	3	3
Belgium	1	—	1	3
Bulgaria	—	2	2	2
Cyprus	—	1	1	2
Czech Republic	—	1	2	2
Denmark	—	1	1	2
Estonia	—	—	1	1
Finland	—	1	1	2
France	—	2	3	2
Germany	4	2	3	3
Greece	—	1	3	2
Hungary	—	1	1	2
Ireland	1	—	—	3
Italy	1	4	4	3
Latvia	1	—	1	3
Lithuania	—	1	2	2
Luxembourg	—	—	1	1
Malta	—	—	1	1
Netherlands	—	1	1	2
Poland	—	1	3	2
Portugal	—	1	2	2
Romania	—	1	3	2
Slovakia	—	—	2	1
Slovenia	1	—	1	3
Spain	—	2	3	2
Sweden	1	1	2	3
UK	1	—	1	3
EU27	8/27	18/27	26/27	

Table 25 Criteria for allocating scores

Score		
3		Patient contact society
2		Patient support society with no patient contact
1		No patient outreach

help line), societies that are patient-orientated but without patient contact and scientific societies that have no outreach to patients. A high score was allocated to those countries with a patient-contact/support society. In its absence, an intermediate grade was allocated to patient-orientated societies and the lowest score to countries with scientific societies and no patient outreach.

Results

The individual societies are listed in the acknowledgements. The distribution of type of society and number by member state is shown in Table 24. Eight countries had a patient-contact society. For patient-orientated societies, there were 26 societies in 18 member states. There were 49 scientific societies in 26 member states (the exception was Ireland).

Score criteria

Support societies was categorised by patient contact (Table 25). A high score was allocated to those countries with a patient-contact society. In its absence, an intermediate grade was allocated to patient-orientated societies and the lowest score to countries with scientific societies and no patient outreach.


Score allocation

The score for each country by score and rank is shown in Fig. 19.

Comment

The score is based on the audit by the IOF of its affiliated societies. As such, it necessarily did not consider societies that are not members of the IOF Committee of National Societies. This consideration should temper the interpretation of this element.

Fig. 19 Society support to osteoporosis by score [IOF audit]



Chapter 3. Service provision

3a Treatments for osteoporosis

Domain

Service provision—scorecard element

Background and aims

A wide variety of approved drug treatments is available for the management of osteoporosis. Potential limitations of their use in member states relate to reimbursement policies which may impair the delivery of health care.

The aim of this scorecard element was to review the provision of medical intervention in each member state and, in particular, to determine whether restricted reimbursement was considered an obstacle to the accessibility and long-term uptake of interventions.

Methods

Information on access to treatment [1] was updated by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012. Information requested included the treatments that are currently reimbursed, the level of reimbursement, the conditions on which reimbursement are offered and whether reimbursement policy interferes with what patients could accept or physicians in each country would wish to recommend to patients. We additionally asked whether there are designated first-line treatments in each country.

The following interventions were included: the bisphosphonates (alendronate, ibandronate, risedronate and zoledronic acid), raloxifene, denosumab, strontium ranelate, parathyroid hormone derivatives (PTH and teriparatide) and vitamin D analogues (alfacalcidol and calcitriol). We excluded gonadal steroids (prescribed for hypogonadal states rather than for osteoporosis) and calcium/vitamin D products (most usually available without prescription).

Costs for first- and second-line treatment per year (weighted on price and market share in each country) were taken from Hernlund [2].

The available information was scored on the basis of full or partial reimbursement. In those countries with restricted reimbursement, countries were identified where reimbursement policy interfered with what patients could accept or physicians would wish to recommend to patients.

Results

Most interventions were reimbursed in most countries. Full reimbursement was provided in only 7 of 26 EU member states (Table 26). In the remaining countries, the level of reimbursement ranged from 0 (Malta) to up to 100 % for selected treatments (Luxembourg and Spain). Restricted reimbursement was reported as a significant obstacle to accessibility and long-term uptake in several countries. Examples include unaffordable cost to the patient (Spain), age restrictions for some agents (Belgium, Italy, Poland), less reimbursement in the absence of a prior fracture (Estonia), and reimbursement for some or all agents conditional on a specialist referral (Czech Republic, Greece and Hungary).

In several countries, reimbursement was conditional on clinical criteria, which prevented health care professionals from prescribing some or all agents to individuals at high risk. Examples include reimbursement criteria based on BMD alone (i.e. irrespective of prior fractures in osteopenic cases) (Bulgaria, Lithuania, Romania), patients at high risk identified by FRAX (Belgium). In France, the intricacies of reimbursement are considered as too complicated by GPs so that many have lost interest in managing the disease. As might be expected, impedimenta were less frequent in those countries with full reimbursement (7/8) than in those with incomplete reimbursement (10/19).

First-line drugs were mandated in 18 of 29 countries. The majority comprised the oral bisphosphonates and, in particular generic alendronate.

As expected, the average cost of intervention (weighted on price and market share in each country) varied markedly and ranged from € 160 (Belgium) to € 1269 (Denmark). There was similar price inequality for generic alendronate (Table 26).

In several countries, some registered treatments were not reimbursed which are listed by treatment in Table 27.

Score criteria

The highest score was allocated for full reimbursement. In those countries with restricted reimbursement, countries were identified where reimbursement policy interfered with what patients could accept or physicians would wish to recommend to patients. Categories are shown in Table 28.

Table 26 Levels of reimbursement, reported barriers to care from reimbursement policies and costs of treatment [IOF audit]

	Reimbursed (%)	Patient or professional impediment	First-line drugs identified	Average cost (€/year)	Generic alendronate (€/year)
Austria	100	No	Yes	257	174
Belgium	10–20	Yes	Yes	160	123
Bulgaria	25	Yes	No	179	80
Cyprus	100 ^a	No	No	640	327
Czech Republic	50–90	No	Yes	359	187
Denmark	50–90	No	Yes	1269	126
Estonia	50–90	Yes	No	232	171
Finland	40	No	Yes	205	40
France	30–65	Yes	Yes	412	209
Germany	100	No	Yes	619	245
Greece	Part	Yes	No	391	239
Hungary	70–90	Yes	Yes	354	115
Ireland	100 ^a	No	No	570	240
Italy	100	Yes	No	619	294
Latvia	50	No	nr	308	85
Lithuania	50–80	Yes	Yes	409	146
Luxembourg	80–100	No	No	336	109
Malta	0	No	Yes	545	190
Netherlands	100	No	Yes	226	4
Poland	30	Yes	No	581	245
Portugal	69	No	Yes	313	16
Romania	50	Yes	Yes	173	53
Slovakia	90+	No	Yes	401	16
Slovenia	100	No	Yes	234	161
Spain	50–100	Yes	Yes	478	201
Sweden	100	No	Yes	667	27
UK	100	No	Yes	226	13

^aDepending on income; *nr* not recorded;

Score allocation

Countries, ranked and categorised by score, are shown in Fig. 20.

Table 27 Registered treatments that are not reimbursed [2]

Treatment	Countries where reimbursement is not offered for osteoporosis
Risedronate	Estonia, Malta
Alendronate	Malta
Ibandronate	Malta, Poland, Sweden
Zoledronic acid	Estonia, Malta, Poland, Romania
Raloxifene	Bulgaria, Latvia, Malta, Poland
Denosumab	Estonia, France, Malta, Portugal, Romania
Strontium Ranelate	Malta, Poland
Teriparatide and PTH (1–84)	Bulgaria, Estonia, Luxembourg, Malta, Netherlands, Poland, Romania
Alfacalcidol/calcitriol	Belgium, Denmark, France, Ireland, Poland

Comment

Note that full reimbursement does not necessarily denote full access to treatment. For example, in Germany and the UK, the availability of drugs other than generic alendronate is restricted, sometimes severely so, by regional or local budgetary policies.

Table 28 Criteria for allocating scores





Score		
3		Full reimbursement
2		Restricted reimbursement with few patient/professional impedimenta
1		Restricted reimbursement with significant patient/professional impedimenta

Fig. 20 Ranking and score for access to medical intervention [IOF audit]. *See comment below [IOF audit]



The large price range of generic alendronate (€4 to €294 per year) is remarkable as an index of inequality of provision within the EU.

References

1. International Osteoporosis Foundation (2008) Osteoporosis in the European Union in 2008: Ten years of progress and ongoing challenges. IOF, Nyon. Available at www.iofbonehealth.org accessed 23rd Sept 2012
2. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos, in press

3b Availability of DXA

Domain

Service provision—scorecard element

Background and aims

The assessment of bone mass forms a cornerstone for the general management of osteoporosis being used for diagnosis, risk prediction, selection of patients for treatment and monitoring of patients on treatment. The appropriate sites and technology are measurement at the lumbar spine and hip with dual-energy X-ray absorptiometry (DXA). The capacity

to service these needs depends therefore on the availability of equipment.

The aim of this score card element was to compare the availability of DXA in the EU member states.

Methods

An estimate of the number of operational DXA machines was determined from the combined sales information of the three major providers (GE Lunar, Hologic and Norland) provided in confidence to the IOF [1]. The metric for each country was the number of DXA units/million of the general population.

Table 29 The number of central DXA units available in the EU27 per million of the general population [1]

Country	DXA units/ million	Country	DXA units/ million	Country	DXA units/ million
Austria	28.7	Germany	21.1	Netherlands	10.7
Belgium	53	Greece	37.5	Poland	4.3
Bulgaria	1.2	Hungary	6.0	Portugal	26.9
Cyprus	23.9	Ireland	10.0	Romania	2.4
Czech Republic	5.2	Italy	18.6	Slovakia	10.7
Denmark	14.6	Latvia	4.9	Slovenia	27.1
Estonia	8.9	Lithuania	3.4	Spain	8.4
Finland	16.8	Luxemburg	2.0	Sweden	10.0
France	29.1	Malta	9.7	UK	8.2

Table 30 Criteria for allocating scores

>18/million		May have adequate provision
8.4-18/million		Borderline provision
<8.4/million		Very inadequate provision

Results

The number of DXA units expressed per million of the general population varied markedly in the EU (Table 29). Belgium, Greece and France were the most well provided for and Bulgaria, Luxembourg and Romania the least. Previous surveys have indicated a marked heterogeneity in the availability of DXA in the EU [2–4] and the present survey, based on manufacturer sales, confirms this finding (Fig. 21).

Score criteria

The score was based on the number of DXA units/million of the general population categorised by tertiles given in Table 30.

Score allocation

Countries, ranked and categorised by score, are shown in Fig. 21.

Comment

The requirement for assessing and monitoring the treatment of osteoporosis to implement practice guidelines has been


estimated at approximately 11 DXA units per million of the general population [2]. The survey indicated that about 50 % of countries in the EU had the recommended number of DXA machines for their population. It is important to note that the figures provided do not distinguish between machines dedicated in part or in full to clinical research, and those that lie idle or are underutilised because of lack of funding. It is likely, therefore, that a majority of countries are under-resourced in the context of their practice guidelines.

The granularity of the data means that it is not possible to determine the use of DXA equipment (for research or service), the efficiency and quality of service or the extent of inequity of geographic distribution of DXA machines.

References

1. Kanis JA (2011) Personal communication, data on file.
2. Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. *Osteoporos Int* 16: 229–38
3. International Osteoporosis Foundation (2008) Osteoporosis in the European Union in 2008: Ten years of progress and ongoing challenges. IOF, Nyon. Available at www.iofbonehealth.org accessed 23rd Sept 2012
4. International Osteoporosis Foundation (2010) The Eastern European and Central Asian regional audit. Epidemiology, cost and burden of osteoporosis in 2010. IOF, Nyon. Available at www.iofbonehealth.org accessed 23rd Sept 2012

Fig. 21 DXA units/million of the general population in 2010 based on sales of DXA in the EU supplied by manufacturers [1]. The horizontal line denotes a minimum service requirement [2]



3c Access to DXA

The aim of this background element was to compare the access to DXA in the EU member states.

Domain

Service provision—Scorecard element

Methods

Background and aims

The assessment of osteoporosis does not solely depend on the availability of bone mass measurements at the lumbar spine and hip with dual-energy X-ray absorptiometry (DXA) (see chapter 3b). Access also depends upon the efficiency with which the technology is used, the ease of patient access (e.g. travelling time), regulatory constraints and barriers to reimbursement.

Data were acquired by means of an IOF questionnaire sent to the EU Osteoporosis Consultation Panel undertaken in December 2012. Respondents were asked to update previous estimates for the cost, waiting time and reimbursement for DXA. Where information was lacking, data for waiting times and reimbursement were taken from the 2008 IOF EU audit or the Eastern European and Central Asian Audit [1, 2]. Respondents were specifically invited to comment on whether the

Table 31 Cost and reimbursement of DXA [IOF audit]


Country	Waiting time (d)	Cost (€)	Reimbursement	Barriers to clinical practice
Austria	14	35	Yes	For some indications and <65 years
Belgium	14	42.5 ^a	Partial	Yes, in case of rather low-risk profile
Bulgaria	0	37.5 ^a	None	Depends on income
Cyprus	20	70	Yes (depending on income)	n.r.
Czech Republic	40 ^a	25	Yes	For some indications
Denmark ^b	30	35	Yes	No
Estonia	14	17	Yes	n.r.
Finland	1	105 ^a	Yes	No
France	14	40	Yes (conditional)	Dependent on clinical risk factors. Algorithm is considered as too complicated for most GPs
Germany	0	45	Yes	Reimbursed only after fracture
Greece ^b	11 ^a	52	Yes	No
Hungary	15 ^a	30	Yes	Reimbursed only for women
Ireland	140 ^{a b}	100	Yes (conditional)	Reimbursed if privately insured. Otherwise, depending on income
Italy	83 ^a	50 ^a	Yes (conditional)	For some indications
Latvia	10 ^a	23.5 ^a	Yes	No
Lithuania	6 ^a	21.5 ^a	No	No
Luxembourg	30	35 ^a	Yes	No
Malta	105 ^a	184 ^b	Yes	For some indications
Netherlands	14 ^a	105	Yes	No
Poland	1	20 ^a	Yes (conditional)	Reimbursement only if seen by specialists
Portugal	8	50 ^a	Yes	No
Romania	7	22.5 ^a	Yes	Yes
Slovakia	18 ^a	30	Yes	No
Slovenia	11 ^a	40	Yes (conditional)	Reimbursement only for secondary osteoporosis
Spain	105 ^a	41 ^a	Yes	No
Sweden	60	90	Yes	No
UK	11 ^a	99	Yes	Yes

n.r.: Data not recorded

^aAverage of range

^bData from [1]

Fig. 22 Reported average waiting time for a DXA assessment by EU country [IOF audit]



reimbursement policy (or lack of reimbursement) provided barriers to the physician's assessment of patients.

Results

The average waiting time for DXA ranged from 0 (Bulgaria and Germany) to 140 days (Ireland) (Table 31 and Fig. 22). There was no clear relation between waiting times and the availability of DXA (see chapter 3b). For example, the average waiting time in Italy was reported to be 83 days, though the number of DXA machines is high (18.6 machines/million of the general population). This disparity arises because many of DXA units lie in research centres or the private sector and are unavailable to the majority of the population. Conversely, there is no waiting time in Bulgaria where the provision of DXA is low (1.2 DXA units/million). The latter observation reflects the fact that the few machines available are only used to service specialised departments and that BMD assessments are unavailable to the vast majority of the population at risk. Thus, a disparity between the availability of equipment and waiting time identifies a high heterogeneity in the use of BMD to assess osteoporosis. A further consideration is the uneven geographical location of equipment, which is known to be problematic in Italy, Spain and the UK.

Reimbursement for DXA scans varied widely between member states both in terms of the criteria required and level of reimbursement awarded, and a majority of countries provided full reimbursement (Table 31). In others, reimbursement or partial reimbursement was limited and usually dependent on physician referral for approved indications, sometimes restricted to criteria that did not satisfy the requirements of good clinical practice. An example is seen

in Bulgaria (and incidentally in Switzerland) where reimbursement is only offered if the BMD test turns out to be positive (i.e. shows osteoporosis). Other examples of restricted access included reimbursement only for limited indications (Austria, Czech Republic, Malta and Slovenia), only if seen by a specialist (Poland), only for women (Hungary) and only after fracture (Germany).

The cost of DXA also varied widely (Table 31) and bore little relation to the wealth of the nation or to the availability of DXA machines.

Score criteria

The highest score was allocated for unconditional reimbursement. In those countries with restricted reimbursement, countries were identified where reimbursement interfered with what patients could accept or physicians would wish to recommend to patients. Categories are shown in Table 32.


Score allocation

Countries, ranked and categorised by score, are shown in Fig. 23.

Table 32 Criteria for allocating scores

Score		
3		Full reimbursement
2		Restricted reimbursement with few patient/professional impedimenta
1		Restricted reimbursement with significant patient/professional impedimenta
0		No information provided

Fig. 23 Categorisation of access to DXA by score in the EU27 [IOF audit]



Comment

There is a remarkable disparity between the availability of equipment and waiting time, which reflects a high heterogeneity in the use of BMD to assess osteoporosis. Unimpeded access to DXA is confined to a minority of member states.

References

1. International Osteoporosis Foundation (2008) Osteoporosis in the European Union in 2008: Ten years of progress and ongoing challenges. IOF, Nyon. Available at www.iofbonehealth.org accessed 23rd Sept 2012
2. International Osteoporosis Foundation (2010b) The Eastern European and central asian regional audit. Epidemiology, cost and burden of osteoporosis in 2010. IOF, Nyon. Available at www.iofbonehealth.org accessed 23rd Sept 2012

3d Access to risk assessment algorithms

Domain

Service provision—scorecard element

Background and aims

The effective targeting of treatment to those at highest risk of fracture requires an assessment of fracture risk. Historically, the targeting of treatment became feasible with the advent of bone mineral density measurements. The causation of fragility fractures is, however, heterogeneous and many additional factors have been identified that contribute to fracture risk. In turn, this has led to the development of risk algorithms that can enhance the assessment of fracture risk to better target interventions, particularly in primary care.

There are several assessment tools available in Europe [1–5]. The most widely used is FRAX®. FRAX is a computer-based algorithm (<http://www.shef.ac.uk/FRAX>) that calculates the 10-year probability of a major fracture (hip, clinical spine, humerus or wrist fracture) and the 10-year probability of hip fracture. Fracture risk is calculated from age, body mass index and well validated dichotomized risk factors. Femoral neck bone mineral density (BMD) can be optionally input to enhance fracture risk prediction. Fracture probability differs markedly in different regions of the world so that FRAX is calibrated to those countries where the epidemiology of fracture and death is known (currently 50 countries). In addition to the web site, FRAX has been incorporated into the software of densitometers and is available as an application for the iPhone/iPad.

The aim of this scorecard element was to document the availability of country-specific risk assessment models (their uptake is considered separately in Chapter 4b). The score was based on the availability of risk assessment models and specific guidance for their use.

Methods

The availability of country-specific FRAX models was provided at the FRAX web site. The availability of other risk engines was determined from an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012 together with a review of country-specific assessment guidelines. The metrics sought were the availability of country-specific risk models and whether national guidance was provided on how results from these assessments should be used in clinical practice.

Results

Risk assessment models were available in 21 of the member states (Table 33). The majority were based on FRAX. In Germany, probability-based fracture risk assessment comprises a component of national guidelines, but is not FRAX-based [1]. Alternative assessment algorithms are also available in the Netherlands [3]. In the UK both FRAX and QFracture has been approved [6]. No models are available for Bulgaria, Cyprus, Estonia, Latvia, Luxembourg and Slovenia due to the lack of appropriate epidemiology of fracture on which these could be based. In countries where a model is available, a small

Table 33 Provision of risk assessment models in the EU and guidance on their application to clinical practice

	FRAX model available	Other models	Guidance	Comments
Austria	✓	–	✓	
Belgium	✓	–	✓	
Bulgaria	–	–	–	
Cyprus ^a	–	–	–	
Czech Republic	✓	–	No	
Denmark	✓	–	No	
Estonia	–	–	–	
Finland	✓	–	✓	
France	✓	–	✓	
Germany	✓	Yes	✓	DVO model [1]
Greece	✓ ^b	–	✓	
Hungary	✓	–	✓	
Ireland	✓ ^b	–	– ^c	
Italy	✓	–	– ^c	
Latvia	–	–	– ^c	
Lithuania	✓ ^b	–	No	
Luxembourg	–	–	– ^c	
Malta	✓	–	No	
Netherlands	✓	Yes	✓	CBO [3]
Poland	✓	–	✓	
Portugal	✓ ^b	–	✓	
Romania	✓	–	– ^c	
Slovakia	✓	–	No ^a	
Slovenia	–	–	No	
Spain	✓	–	No	
Sweden	✓	–	✓	
UK ^d	✓	Yes	✓	QFracture [2]
Europe	–	–	✓	

^a Uses Greek FRAX tool as a surrogate model

^b Available from June 2012 and September 2012 (Portugal);

^c Noted in guidelines but without guidance; ^c to be implemented.

^d Guidance not provided by NICE

Table 34 Criteria for allocating scores

Score		
3		Fracture risk assessment model available with guidance on its use
2		Fracture risk assessment model available but no guidance on its use
1		Fracture risk assessment model not available

majority (12/21) provide guidance on its application to clinical practice.

European guidance that can be applied to member states has been recently published for postmenopausal and glucocorticoid-induced osteoporosis [7, 8].

Score allocation

The score was based availability of country-specific risk models and whether national guidance was provided on how results from these assessments should be used in clinical practice as given in Table 34.

The score assigned to each country is shown in Fig. 24.

Comment

Risk assessment models for fractures based on FRAX were available in 21 out of 27 countries. In some countries (UK, Germany and the Netherlands) other models are also available. However, guidance on the use of risk assessment was available in only 12 out of 27 countries.




Fig. 24 The score assigned to each country on the basis of its provision of fracture risk assessment algorithms. The star denotes that guidance given by the National Osteoporosis Guideline Group scores 3 but the score based on NICE is less

References

1. Dachverband Osteologie e.V (2011) DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteologie 20: 55–74. Accessible at: <http://www.schattauer.de/en/magazine/subject-areas/journals-a-z/osteology/contents/archive/issue/special> (Accessed May 2012)
2. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. *BMJ*. 2012 May 22;344:e3427.
3. Dutch Institute for Healthcare Improvement (CBO). Richtlijn Osteoporose en fractuurpreventie, derde herziening. Utrecht: CBO; 2011.
4. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey EV (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. *Osteoporos Int* 19: 385–397.
5. Kanis JA on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. Access at http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf
6. National Institute for Clinical Excellence (2012) Osteoporosis: assessing the risk of fragility fracture. Clinical guideline 146. www.nice.org.uk/CG146
7. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 24: 23–57.
8. Lekawasam S, Adachi JD, Agnusdei D et al. for the Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporos Int* 23:2257–76.

3e Quality of guidelines for assessment and treatment

Domain

Service provision—scorecard element

Background and aims

The aim of guidelines is to provide an information platform for the assessment and treatment of osteoporosis so that appropriate treatment is directed to individuals at high fracture risk. Their scope most commonly includes postmenopausal osteoporosis, glucocorticoid-induced osteoporosis and osteoporosis in men. Less commonly, guidelines are available for the assessment of falls risk and its treatment. Ideally, guidelines should be based on systematic literature reviews and any recommendations supported by an adequate level of evidence.

The aim of this scorecard element was to determine the scope and quality of guidelines available in the EU27 countries.

Table 35 Availability and scope of guidelines for the assessment and treatment of osteoporosis in the EU [IOF audit]

	Developed (year)	Scope ^a	AGREE criteria	Score
Austria	2010	PMW, men, GIOP	5	8
Belgium	2005–11	PMW, men, GIOP	4	7
Bulgaria	2007	PMW, men, GIOP	6	9
Cyprus	na	–	0	0
Czech Republic	2003–10	PMW, GIOP	4	6
Denmark	2009	PMW	4	5
Estonia	2012	PMW, men, GIOP	5	8
Finland	2013	PMW, men, GIOP	7	10
France	2012	PMW, men, GIOP	5	6
Germany	2009	PMW, men, GIOP	7	10
Greece	2009–12	PMW, men, GIOP	5	8
Hungary	2003–11	PMW, men, GIOP	5	8
Ireland	2011	PMW, men	1	3
Italy	–2011	PMW, men, GIOP	7	10
Latvia	2011	PMW, men, GIOP	7	10
Lithuania	2011	PMW	7	7
Luxembourg	2010	PMW	7	7
Malta	na	–	0	0
Netherlands	2011–12	PMW, men, GIOP	7	10
Poland	2011–12	PMW, men, GIOP	3	6
Portugal	2011	PMW	7	8
Romania	2011	PMW, men, GIOP	6	9
Slovakia	2006–10	PMW, GIOP	7	9
Slovenia	2002	PMW	2	3
Spain	2004–11	PMW, men, GIOP	4.5	6.5
Sweden	2008	PMW, men, GIOP	7	10
UK ^b	2008	PMW, men, GIOP	7	10

^a *PMW* postmenopausal women, *GIO* glucocorticoid-induced osteoporosis

^b Relates to guidance provided by the National Osteoporosis Guidelines Group [4]. National guidance with less scope also available from NICE [5–7]

Table 36 Criteria for allocating scores




Score		
9 or 10		Extensive and high quality guidelines
7 or 8		Intermediate scope or quality
≤6		Poor scope or quality
0		No guidelines available

Fig. 25 Score allocation based on the scope and quality of guidelines available for the assessment and treatment of osteoporosis. For the UK (star), the score for guidance provided by NICE is 8 and that provided by the National Osteoporosis Guidelines Group has a score of 10 [IOF audit]



Methods

Data were acquired by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012. Respondents were asked whether national guidelines were available for the assessment and/or treatment of osteoporosis. Responses were used to update an earlier audit of the IOF [1, 2]. Where guidelines were available, additional information was requested on their scope and quality.

Scope of guideline: Does it relate to postmenopausal women (PMW), men or glucocorticoid-induced osteoporosis (GIOP).

AGREE criteria: The quality of guidelines was judged according to the criteria developed the Appraisal of guidelines for research & evaluation (AGREE) next steps consortium [3] under 7 general domains (see footnote¹).

¹ AGREE criteria

Systematic search. How thorough was the evidence base? Were the guidelines based on a systematic literature review conducted at the time of the guideline development (or on a previously conducted review that was updated).

Recommendations: Were recommendations graded (e.g. A, B, C) according to the levels of evidence provided by the systematic review?

Stakeholder involvement: Was there involvement from patient organisations, primary care physicians, national/EU societies in the consultation process for the guidelines?

External review: Were the guidelines reviewed by independent experts? i.e. have they undergone a rigorous external review in addition to consultation.

Procedure for update: Were the guidelines updated as and when necessary or was there explicit mention of a provision to update the guidelines in the future?

Economic analysis: Were the recommendations underpinned by an economic analysis?

Editorial independence: Did the guidelines explicitly state that there was editorial independence of the writing group from any funding body?

Results

Guidelines for the management of osteoporosis were available in the majority of member states (unavailable in Cyprus and Malta). All of the remaining countries had guidelines available for postmenopausal women (Table 35). 17 of 25 countries had guidelines for osteoporosis in men and 19 had guidelines for glucocorticoid-induced osteoporosis. The availability of guidelines does not necessarily improve disease management and in some countries (e.g. Italy, Spain and UK) multiple guidelines were available from different sources that are likely to confuse rather than clarify clinical practice.

Score criteria

A positive response in each AGREE category contributed a point to the score (maximum 7 points). Up to 3 additional points was given for the scope of the guideline (PMW, men, GIOP) to give a maximum score of 10. Where more than one guideline was available, a composite mean was used. Scores for each country were categorised as shown in Table 36.

Score allocation

The score allocation and grade for each country is shown in Fig. 25.

Comment

There was a large variation in the extent and quality of national guidelines according to the AGREE criteria. It should be noted that a high score reflects the quality of the process, but not necessarily the quality of the content.

References

1. International Osteoporosis Foundation (2010) Osteoporosis in the European Union in 2008. Ten years of progress and ongoing challenges. Updated Aug 2010. International Osteoporosis Foundation, Nyon. Available at www.iofbonehealth.org accessed 23rd Sept 2012
2. International Osteoporosis Foundation (2010) The Eastern European and central Asian regional audit. Epidemiology, cost and burden of osteoporosis in 2010. IOF, Nyon. Available at www.iofbonehealth.org accessed 23rd Sept 2012
3. The AGREE next steps consortium (2009) Appraisal of guidelines for research & evaluation II. AGREE Research Trust, McMaster University, Hamilton, Ontario, Canada. Available at <http://www.agreetrust.org> Accessed December 2012
4. Compston J, Cooper A, Cooper C et al, on behalf of the National Osteoporosis Guideline Group (NOGG) (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. *Maturitas*; 62:105–108.
5. National Institute for Clinical Excellence (2008) Technology Appraisal (TA) 160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) <http://www.nice.org.uk/nicemedia/live/11746/47176/47176.pdf>
6. National Institute for Clinical Excellence (2008) Technology Appraisal (TA) 161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women <http://www.nice.org.uk/nicemedia/live/11748/42508/42508.pdf>
7. National Institute for Clinical Excellence (2010) Technology Appraisal (TA) 204: Osteoporotic fractures—denosumab <http://www.nice.org.uk/nicemedia/live/13251/51293/51293.pdf>

3f Guideline criteria for assessment and treatment

Domain

Service provision—supplementary information

Background and aims

The aim of this section was to summarise the differences in the application of guidelines to clinical practice and, in particular, to identify where guideline recommendations conflicted with reimbursement policy.

Methods

A review was undertaken of guidelines covering the assessment and treatment of osteoporosis in each EU member state that was available in English or French. Additionally, data were acquired from a structured IOF questionnaire administered to the EU Osteoporosis Consultation Panel undertaken in December 2012. Information requested included whether

guidelines addressed population-based screening, the tools used for assessment, and the tools to decide eligibility for treatment. An enquiry was also made whether risk assessment or treatment recommendations were compatible with reimbursement policy.

Results

Guidelines were not available in Cyprus or Malta. In the remaining countries, guidelines were generally less than 5 years old, often related to updating, with one exception (Slovenia, 2002).

Population screening was considered in guidelines from 15 of 25 countries. Although reviewed, population based screening was not recommended. In Hungary, however BMD is offered free of charge to women aged 50 years or more, though the uptake is low.

Guidelines in 24 of the 25 countries covered the assessment of fracture risk (the exception was the Czech Republic). The most common tools used for fracture risk assessment were age in 22/25 countries (exceptions were Lithuania, Slovakia and Sweden) and bone mineral density (in all countries). The use of fracture risk assessment algorithms was less consistent and noted in 17 countries (Fig. 26). FRAX was the most widely used instrument though in Germany the DVO tool was recommended [1]. In the UK, both FRAX and QFracture has been approved [2].

Guidelines in all 25 countries covered eligibility for treatment with a general commonality of approach. Eligibility for treatment depended on prior fracture (except Denmark and Sweden), age (except Lithuania, Slovakia and Sweden) and BMD (all countries). As was the case for assessment (see Chapter 3d), risk assessment tools provided criteria for intervention in fewer (17/25) countries (Fig. 26). In Italy, Spain and the UK, there are several guidelines from different sources that give different recommendations.

Several countries reported incompatibilities between recommendations for risk assessment or treatment with reimbursement policy (Table 37). For example, guidelines




Fig. 26 The distribution of the use of risk assessment models in assessment guidelines of the EU27 countries [IOF audit]

recommended the use of FRAX which was not provided for in reimbursement provision (Belgium, Poland, Romania and Slovakia), specific treatments were recommended but not reimbursed (Poland, Romania) and central DXA was recommended for risk assessment but other techniques (peripheral BMD and QCT) were reimbursed (Lithuania). In Luxembourg, the BMD thresholds for treatment differ from the criteria for reimbursement for DXA. In other instances, guidelines recommended the use of risk factors such as a prior fragility fractures but reimbursement was solely dependent on BMD (Lithuania, Romania). With regard to treatment, reimbursement was limited in time (18 months) but treatment recommended on a long-term basis (Lithuania). A problem inconsistently related to reimbursement was that multiple guidelines gave conflicting recommendations (Italy, Spain, and the UK). Another barrier to treatment is that reimbursement was only granted where the prescription was issued by a specialist (e.g. Czech Republic).

Table 37 Scope of guidelines for patient assessment, treatment and consistency with reimbursement policy [IOF audit]

	Date	Assessment	Compatible/ consistent	Treatment	Compatible/ consistent
Austria	2010	Yes	Yes	Yes	Yes
Belgium	2005–11	Yes	No	Yes	No
Bulgaria	2007	Yes	No	Yes	No
Cyprus	na	–	–	–	–
Czech Republic	2003–10	No	No	Yes	No
Denmark	2009	Yes		Yes	Yes
Estonia	2012	Yes	Yes	Yes	Yes
Finland	2013	Yes	Yes	Yes	Yes
France	2012	Yes	Yes	Yes	Yes
Germany	2009	Yes	No	Yes	No
Greece	2009	Yes	Yes	Yes	Yes
Hungary	2011	Yes	Yes	Yes	Yes
Ireland	2011	Yes	No	Yes	Yes
Italy	–2011	Yes	Yes/no	Yes	No
Latvia	2011	Yes	Yes	Yes	Yes
Lithuania	2011	Yes	No	Yes	No
Luxembourg	2010	Yes	No	Yes	Yes
Malta	na	–	–	–	–
Netherlands	2011–12	Yes	Yes	Yes	Yes
Poland	2011–12	Yes	No	Yes	No
Portugal	2011	Yes	Yes	Yes	Yes
Romania	2011	Yes	No	Yes	No
Slovakia	2006/09/10	Yes	No	Yes	Yes
Slovenia	2002	Yes	Yes	Yes	Yes
Spain	2004–11	Yes/no	Yes/no	Yes/no	Yes
Sweden	2012	Yes	Yes	Yes	Yes
UK	2008–12	Yes	Yes/no	Yes	Yes

na not applicable, nr not recorded

Score allocation

Supplementary information, no score allocation

Comment

Risk assessment or treatment recommendations were compatible with reimbursement policy in approximately half of the EU member states.

References

1. Dachverband Osteologie e.V (2011) DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteologie 20: 55–74. Accessible at: <http://www.schattauer.de/en/magazine/subject-areas/journals-a-z/osteology/contents/archive-issue/special> (Accessed May 2012)
2. National Institute for Clinical Excellence (2012) Osteoporosis: assessing the risk of fragility fracture. Clinical guideline 146. www.nice.org.uk/CG146

3g Fracture liaison services

Domain

Service provision—scorecard element

Background and aims

Fracture liaison services (FLS), also known as osteoporosis co-ordinator programmes and care manager programs, provide a system for the routine assessment and management of postmenopausal women and older men who have sustained a low trauma fracture [1–4]. Assessment includes DXA measurements, fall risk evaluation, and underlying secondary causes of osteoporosis. Although the importance of an incident fracture as a risk factor for further fracture is well recognised, the majority of patients presenting with a low trauma fracture do not receive appropriate assessment and treatment in the setting of standard hospital care. FLS address this need through a systematic approach to identifying such individuals and assessing their risk of further fractures and the need for treatment. Most FLS are based in secondary care although models in primary care have also been described. The clinical and cost-effectiveness of FLS has been demonstrated in several centres [5–7].




Fig. 27 The proportion of hospitals (%) with FLS in the EU countries [IOF audit]

The aim of this scorecard element was to document the proportion of hospitals that have a fracture liaison service in the EU27 countries.

Methods

Information was acquired from a structured IOF questionnaire administered to the EU Osteoporosis Consultation Panel undertaken in December 2012. Correspondents were asked to estimate the proportion of hospitals in each member state that have a scheme in place that refers fracture patients over 50 years old to a fracture liaison service. Scoring was based on the distribution of the estimates.

Results

No estimates were provided from Malta. Of the remaining countries, no fracture liaison services were reported from Greece, Latvia, Portugal, Romania and Slovakia. The presence of FLS was acknowledged in the remaining member states, but for most countries, the proportion of hospitals that have a scheme in place was less than 10 %. Higher rates were reported from Austria, Cyprus, Czech Republic, Estonia, Finland, Hungary, Netherlands and Sweden (Fig. 27).

Table 38 Criteria for allocating scores

Score		
3		FLS in >10% of hospitals
2		FLS in 1-10% of hospitals
1		No FLS
0		not recorded




Fig. 28 Scores allocated by country on the availability of fracture liaison services in hospitals by member state [IOF audit]

Score criteria

The proportion of hospitals in each member state that had fracture liaison services (FLS) in place were categorised as shown in Table 38.

Score allocation

Figure 28 shows the scores allocated by country

Comment

The information provided needs to be interpreted cautiously. It provides a perception of how many hospitals of a country has a fracture nurse working in a fracture liaison service, but is an expert opinion and not based on numerical evidence. Moreover, no account was taken of FLS in primary care. In addition, no information was available on the performance of the FLS. It is also notable that a colour code of green should not be interpreted as an endorsement since provision should, in the view of the panel, be expected in the majority of hospitals or care centres.

References

- Cooper C, Mitchell P, Kanis JA (2011) Breaking the fragility fracture cycle. *Osteoporos Int* 22:2049–50.
- Eisman JA, Bogoch ER, Dell R et al. (2012) Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. *J Bone Miner Res* 27: 2039–46
- International Osteoporosis Foundation (2012) Capture the fracture: a global campaign to break the fragility fracture cycle. IOF, Nyön. Accessible at www.iofbonehealth.org

4. Sale JE, Beaton D, Posen J, Elliot-Gibson V, Bogoch E (2011) Systematic review on interventions to improve osteoporosis investigation and treatment in fragility fracture patients. *Osteoporos Int* 22: 2067–82.
5. Dell R (2011) Fracture prevention in Kaiser Permanente Southern California. *Osteoporos Int* 22 (Suppl 3): 457–60
6. Marsh D, Akesson K, Beaton DE, Bogoch ER, Boonen S, Brandi ML, McLellan AR, Mitchell PJ, Sale JE, Wahl DA; IOF CSA Fracture Working Group (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. *Osteoporos Int* 22: 2051–65
7. McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. *Osteoporos Int*. 2011 22: 2083–98.

3h Use of quality indicators

Domain

Service provision—scorecard element

Background and aims

The use of indicators to systematically measure the quality of care provided to people with osteoporosis or associated fractures is a relatively new discipline, with the United States perhaps having the most developed system in place [1], as shown for use of healthcare quality indicators more broadly [2]. In the UK, the Department of Health Best Practice Tariff for hip fracture care has used financial incentives since April 2010 to drive adherence with the six core benchmarks, which include an assessment of bone health and risk of falling. In the 2 years following introduction of the tariff, the proportion of patients with fragility hip fracture for whom all six standards were met rose from 24 to 55 % [3].

The aim of this scorecard element was to document the systematic approaches to enhance the quality of osteoporosis care or secondary prevention of fragility fractures in the EU.

Methods

Data were acquired by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012. Respondents were asked whether national systems were in place that systematically collect data on the quality of care provided to people with osteoporosis or the secondary prevention of fragility fractures. Further questions were whether the systems use measures (quality indicators or standards) that are documented on a regular basis (e.g. annually) and use a set of explicit criteria to assess performance.

Results

Few countries had systems that include quality measures *plus* a regular audit for national health care agencies (Denmark, Germany, and UK). In the United Kingdom, osteoporosis/ secondary prevention of fragility fractures has been included in the Quality and Outcomes Framework as part of the general practitioner contract from April 2012 [4]. The Quality and Outcomes Framework is a pay for performance scheme for general practice in the UK, which awards ‘achievement points’ for adhering to procedural and treatment guidelines and meeting intermediate outcome targets for over 130 quality indicators. In the UK, there is also a system of clinical audits in place, seeking to improve patient care and outcomes through systematic review of care according to explicit criteria and the implementation of change. These include the National Audit of Falls and Bone Health in Older People [5] and the continuous National Hip

Table 39 Systems that provide quality indicators in the context of osteoporosis and fractures in the European Union [IOF audit]

	Systems in place	Targets	Score
Austria	No		1
Belgium	No		1
Bulgaria	Yes	Hip fractures	2
Cyprus	No		1
Czech Republic	No		1
Denmark	Yes	Hip fractures	3
Estonia	No		1
Finland	Yes	Hip fractures	2
France	No		1
Germany	Yes	Hip fractures	3
Greece	Yes	Hip fractures	2
Hungary	Yes	Fragility fractures	2
Ireland	No		1
Italy	No		1
Latvia	No		1
Lithuania	No		1
Luxemburg	No		1
Malta	No		1
Netherlands	Yes		3
Poland	No		1
Portugal	No		1
Romania	No		1
Slovakia	Yes	Osteoporosis, fragility fracture, falls	2
Slovenia	No		1
Spain	No		1
Sweden	Yes	Fractures, treatment	2
UK	Yes	Hip fracture, falls, fragility fractures	3

Fracture Database [3]. In Germany, selected providers and health insurance funds have, in the framework of ‘integrated care contracts’ entered into agreements on coordinated osteoporosis care which may include the documentation of care standards to enable tracking of the quality of care provided. The nature and contents of these contracts vary across regions [6]. There is a systematic and nationwide collection of quality indicators for the inpatient care following hip fracture [7]; however a systematic collection of indicators that would permit assessment of care quality of those with osteoporosis and in the secondary prevention of fragility fractures is not in place.

Several other counties (Bulgaria, Finland, Greece) have systems that provide quality indicators or standards that are documented on a regular basis (Table 39) but it is unclear whether criteria are developed to assess performance. In Slovakia, quality measures are in place but no provision is made for regular audit.

Score criteria

The score was based on the presence of systems and their use as quality indicators as given in Table 40

Score allocation

Score allocation for quality indicators by country are given in Fig. 29.

Given the relative novelty of using QI for the tracking of quality of care provided to people with osteoporosis or associated fractures in the European region, it should be recognised that the score is a

Table 40 Criteria for allocating scores

Score		
3		Systems and performance criteria
2		Systems but no audit
1		No systems in place




Fig. 29 Score allocation for quality indicators by country [IOF audit]

‘proxy’ measure. Though audited quality measures have been introduced in some countries, the UK is far advanced in this regard.

References

- Conklin A, Yaqub O, Celia C, Nolte E (2012) Postmenopausal osteoporosis management. A review of the evidence to inform the development of quality indicators. Santa Monica: RAND Corporation.
- Nolte E, Roland M, Damberg CL, Matke S, Cacace M, Goshev S, Brereton L, Conklin A, Hiatt L, Quigley DD, Lovejoy SL (2011) Informing the development of a resource allocation framework in the German healthcare system. Santa Monica: RAND Corporation.
- National Hip Fracture Database. Available at <http://www.nhfd.co.uk/>.
- NHS Employers and British Medical Association. Quality and Outcomes Framework for 2012/13. London: NHS Employers, 2012.
- Treml J, Husk J, Lowe D, Vasilakis N (2011) Falling standards, broken promises. Report of the National Audit of Falls and Bone Health in Older People. London: Royal College of Physicians.
- Grothaus F-J. Entwicklung der integrierten Versorgung in der Bundesrepublik Deutschland 2004 – 2008. Gemeinsame Registrierungsstelle zur Unterstützung der Umsetzung des § 140d SGB V, 2009.
- AQUA. Beschreibung der Qualitätsindikatoren für das Erfassungsjahr 2011. Hüftgelenknahe Femurfraktur. Qualitätsindikatoren 2011. [Online] Available at http://www.sqg.de/downloads/QIDB/2011/AQUA_17n1_Indikatoren_2011.pdf (Accessed on 29 June 2012). [also: <http://www.sqg.de/sqg/upload/CONTENT/EN/Quality-Report/AQUA-German-Hospital-Quality-Report-2010.pdf>]

Chapter 4. Service uptake

4a Uptake of DXA

Domain

Service uptake—background information

Background and aims

The ability to assess osteoporosis depends in part on the availability of bone mass measurements at the lumbar spine and hip with dual energy X-ray absorptiometry (DXA). The requirement for the technology will depend on the assessment guidelines in each member state and the policy with respect to the use of DXA to diagnose osteoporosis and monitor treatment. The uptake of this technology depends upon the efficiency with which the technology is used, the ease of patient access (e.g. travelling time), regulatory constraints and barriers to reimbursement.

The aim of this element was to compare the access to DXA measured as a function of the requirements recommended in relevant assessment guidelines.

Methods

Ideally, uptake should be measured as the number of scans undertaken in relation to treatment guidelines in each member state. Such data are not available in the EU as a whole. Data are available by age and sex from the National Health Service of Denmark and are reported here [Abrahamsen, 2011].

Results

The Danish National Health Service release claims data for DXA and was available most recently for 2005. The uptake of BMD testing by age and sex for 2005 is shown in Fig. 30. Although the accuracy of the claims to tests is uncertain and tests in the private sector are not captured, the uptake was very low even accounting for these errors. Thus, guidelines based on BMD testing indicate that 173 women/1,000 women aged 50 years or more qualify for BMD testing [2] whereas the corresponding figure for Denmark was 28.6 or 16 % of the desired uptake. The use of probability-based guidelines reduces the number of scans needed to 81/1000 women [2] but is still considerably higher than that attained in Denmark. The uptake in men over the age of 50 years was 4 times lower (7/1000) than in women. In men and women combined the uptake of DXA was 18.5/1000.




Fig. 30 The uptake of BMD testing in men and women by age and sex in Denmark in 2005 [Data kindly provided by Bo Abrahamsen, Gentofte Hospital Copenhagen, Denmark]

Score allocation

No score allocation

Comment

More information is required from all member states on the utilisation of DXA with regard to guidelines on the assessment and monitoring of treatment. The available evidence from Denmark, a country moderately provided with DXA machines, is that service uptake is less than optimal.

References

1. Abrahamsen B (2011) Personal communication to Kanis JA.
2. Johansson H, Kanis JA, Oden A, Compston J, McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. *Osteoporos Int* 23: 907–915.

4b Uptake of risk assessment algorithms

Domain

Service uptake—scorecard element

Background and aims

FRAX is an algorithm that determines fracture probability in individuals by integrating the weight of important clinical risk factors for fracture and mortality risk, with or without information on BMD (see Chapter 1 g). Each tool is country-specific and calibrated to the national epidemiology of fracture. They were developed by the WHO Collaborating Centre for Metabolic Bone Diseases at Sheffield, UK and launched in 2008 [1, 2]. The FRAX tools (www.shef.ac.uk/FRAX) compute the 10-year probability of hip fracture or a major osteoporotic fracture. A major osteoporotic fracture is a clinical spine, hip, forearm and humerus fracture. The use of the tool improves risk assessment compared to the use of BMD alone.

FRAX is now a component of many national guidelines for the assessment of osteoporosis (see Chapter 3f) and European guidelines for postmenopausal osteoporosis and glucocorticoid-induced osteoporosis [3, 4]. The aim of this element was to determine the usage of FRAX in the EU27 countries.

Methods

Each FRAX model on the web counts the number of calculations performed for that particular country. A problem with these data is that some countries,

particularly those without a country-specific FRAX model, may use a surrogate. For example, the UK model was adopted as a surrogate in Poland before the advent of a Polish model and the Greek model is presently used in Cyprus. For this reason, we assessed the number of calculations by the source of the calculation [Google Analytics]. FRAX usage was computed as the number of calculations originating from each country and expressed as calculations/million of the general population over a period of one year (November 2010 to December 2011).

Results

The web-based usage of the models is shown in Table 41 which shows considerable heterogeneity in uptake. Belgium, UK, Luxembourg, Sweden and Ireland have the highest usage of FRAX. Lithuania, Latvia, Germany and Bulgaria have the lowest uptake. The average uptake for the EU27 was 880 calculations/million of the general population.

Country-specific models are available in 21 member states (see Chapter 3d). FRAX models are not available for Bulgaria, Cyprus, Estonia, Latvia, Luxembourg and Slovenia. There is, however, no clear relationship between the availability of a country-specific model and the use of FRAX.

Score criteria

FRAX calculations/million of the general population/year was categorised by tertiles as given in Table 42

Table 41 Uptake of FRAX in EU counties expressed as the number of calculations per million of the general population

Country	Calculations /million	Country	Calculations /million	Country	Calculations /million
Austria	1534	Germany	83.5	Netherlands	526
Belgium	5003	Greece	502	Poland	338
Bulgaria	112	Hungary	1205	Portugal	1039
Cyprus	272	Ireland	1643	Romania	230
Czech Republic	175	Italy	518	Slovakia	372
Denmark	942	Latvia	57.7	Slovenia	1322
Estonia	207	Lithuania	28.5	Spain	1115
Finland	444	Luxembourg	2293	Sweden	1911
France	314	Malta	1541	UK	2293

Table 42 Criteria for allocating scores

Calculations/million		
>1200	High use	
320-1200	Intermediate use	
<320	Low use	

Score allocation

Countries, ranked and categorised by score, are shown in Fig. 31.

Comment

These data underestimate the use of FRAX by approximately 25 % due to the availability of FRAX on bone densitometers. FRAX calculations on densitometers are not performed through the web site. In addition, hand held calculators are used in several countries, particularly in Poland. FRAX is also available as an application on the iPhone.

These data underestimate the use of risk assessment in Germany. Fracture risk assessment comprises a component of the German national guidelines, but is not FRAX based. Alternative assessment algorithms are also available in the UK and the Netherlands.

The caveats above indicate that the figures are conservative. Even so, there are reasons to believe that FRAX is underutilised.




Fig. 31 The uptake of fracture risk assessment tools as judged by the use of FRAX from each EU country by score category. *See comment below with regard to Germany

For example, the use of FRAX in Denmark (942 calculations/million per year) is much lower than the number of BMD tests/year (18,500 /million per year; see Chapter 4a). Thus, a colour code of green should not be interpreted as an endorsement of appropriate uptake.

References

1. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey EV (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. *Osteoporos Int* 19: 385–397.
2. Kanis JA on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. Access at http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf
3. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 24: 23–57
4. Lekawasam S, Adachi JD, Agnusdei D et al. for the Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporosis International* 23:2257–76.

4c Treatment uptake and treatment gap

Domain

Service uptake—scorecard element

Background and aims

Many surveys indicate that a minority of men and women at high fracture risk receive treatment [1, 2]. The aim of this section was to estimate the proportion of women at high risk that receives therapy for osteoporosis in the EU27.

Methods

The proportion of patients eligible for treatment depends on defining an intervention threshold, i.e. the risk of fracture above which treatment can be recommended. Though treatment guidelines are available in nearly all EU member states [3] (see Chapters 3e and 3f), there is no uniform approach to intervention thresholds across the EU27.

The advent of FRAX (www.shef.ac.uk/FRAX) in 2008 provided a clinical tool for the calculation of

fracture probability that has been applied to the development of intervention thresholds [4]. For the purposes of this analysis, the intervention threshold set was at the 10-year fracture probability equivalent to women with a prior fragility fracture without knowledge of BMD as adopted in several European guidelines [5–7]. Thus, the intervention threshold can be likened to a ‘fracture threshold’ expressed in terms of fracture probability. The proportion of women who exceed the fracture threshold was computed by simulation [8] based on the distribution of the risk-score among the cohorts used by WHO to develop FRAX and the epidemiology of fracture and death in each EU country.

The number of patients treated in each country was computed from IMS Health sales data for 2010 and expressed as treatment years [3]. The use of hormone replacement treatment was excluded since the majority of women take hormone replacement treatment for menopausal symptoms rather than for osteoporosis. An adjustment factor (estimated from data from the Swedish Prescribed Drug Register) was used to correct for

suboptimal adherence. The number of women potentially treated was subtracted from the number of women exceeding the intervention threshold and expressed as a percentage. No sales data were available for Cyprus or Malta and these two countries were therefore excluded from analyses.

Results

Table 43 indicates that there is wide inter-country variation in the treatment penetration of women at high risk for osteoporotic fractures. The treatment gap varied from 25 % in Spain to 95 % in Bulgaria. Large treatment gaps were identified in countries with populations at both high and low risk of fracture. In total in the EU, it is estimated that, out of the 18.4 million women that exceed the risk level, 10.6 million are untreated. These figures are conservative since an undetermined proportion of low-risk women will have received treatment (see comments, below).

Table 43 Number of women eligible for treatment, treated and treatment gap in 2010 [3]

Country	Number potentially treated (000s)	Number exceeding fracture risk threshold (000s)	Difference (000s)	Treatment gap (%)
Austria	139	282	143	51
Belgium	214	402	188	47
Bulgaria	13	240	227	95
Czech Republic	79	330	251	76
Denmark	87	190	103	54
Estonia	7	48	41	86
Finland	53	172	119	69
France	1,390	2,437	1,047	43
Germany	730	3,231	2,501	77
Greece	333	482	149	31
Hungary	238	332	94	28
Ireland	91	124	33	26
Italy	1,069	2,635	1,566	59
Latvia	12	80	68	85
Lithuania	11	109	98	90
Luxembourg	9	16	7	43
Netherlands	242	605	363	60
Poland	245	1,127	882	78
Portugal	269	425	156	37
Romania	100	599	499	83
Slovakia	75	148	73	49
Slovenia	35	62	27	44
Spain	1,277	1,709	432	25
Sweden	100	358	258	72
UK	1,064	2,298	1,234	54
EU27	7,881	18,441	10,560	57

Score criteria

Countries were categorised by approximate tertiles as shown in Table 44.

Score allocation

The score allocation and the treatment gap for each country is shown in Fig. 32.

Comment

It is unlikely that 100 % of sales are captured in any country but it is difficult to define the magnitude of underestimation. IMS Health attempts to correct for under- and over-estimation, and in the absence of any additional information, there is no further adjustment of the available sales figures.

Another difficulty in interpretation may arise from parallel trade. IMS Health adjusts the data for parallel trade in some countries. The countries for which adjustments have been made are Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden and the UK.

The pattern of use within countries cannot be ascertained in this analysis, so that it is not possible to determine whether treatment is targeted appropriately to high risk individuals. There are several indicators that suggest that the targeting of treatment is heterogeneous in the EU27. Good evidence comes from the Global Longitudinal Study of Osteoporosis in Women (GLOW) which is a general practice based observational cohort study in women aged 55 years or more conducted in 10 countries, including several EU countries [1]. In the EU countries, there was heterogeneity of treatment uptake between countries with the lowest proportion of women aged 55 years or more treated in the Netherlands (7 %) and the highest in Spain (23 %) (Fig. 33). Although treatment uptake was higher in women at very high risk (a prior hip or spine fracture), a minority (45 %) were receiving treatment in these countries.

Table 44 Criteria for allocating scores

Treatment gap (%)		Treatment gap
<45		Moderate
45-65		High
>65		Very high




Fig. 32 Proportion of women of women at high risk that are untreated (treatment gap) in 2010 ranked by country and score [3]

Again, there was heterogeneity in treatment uptake that ranged from 36 % in the Netherlands to 57 % in Italy. Moreover, some low-risk women were targeted in all countries.

These data demonstrate that a large number of women at high risk of fractures are not receiving treatment, that a substantial number of women at low risk are prescribed treatment (13–22 %) and confirm important differences in the uptake of treatment between countries. Thus, a colour code of green should not be interpreted as an optimum.

Proportion treated (%)




Fig. 33 Proportion of women receiving treatment in six EU member states according to category of risk. All women refer to women aged 55 years or more ($n=24,249$). Low risk comprises women aged less than 75 years with a T score for BMD in the range of osteopenia, no prior fracture, no maternal hip fracture or osteoporosis ($n=1166$). High risk refers to women reported to have a BMD measurement in the range of osteoporosis ($n=5258$). Very high risk comprises women with a previous hip or spine fracture ($n=913$) [9]

References

1. Díez-Pérez A, Hooven FH, Adachi JD et al. (2011) Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). *Bone* 49: 493–8.
2. Guggina P, Flahive J, Hooven FH et al. (2012) Characteristics associated with anti-osteoporosis medication use: Data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort. *Bone* 51: 975–980
3. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos*, in press
4. Kanis JA, Hans D, Cooper C, et al. (2011) Interpretation and use of FRAX in clinical practice. *Osteoporos Int* 22: 395–411
5. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M; on behalf of the National Osteoporosis Guideline Group (NOGG) (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. *Maturitas*; 62:105–108.
6. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 24: 23–57.
7. Lekawasam S, Adachi JD, Agnusdei D et al. for the Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporos Int* 23:2257–76.
8. Kanis JA, Johansson H, Odén A, McCloskey EV (2012) The distribution of FRAX® based probabilities in women from Japan. *J Bone Miner Metab* 30: 700–5.
9. Hooven FH and the GLOW investigators (2012) Previously unpublished data derived from Díez-Pérez et al., 2011 [1], courtesy of F Hooven and the GLOW investigators

Methods

The National Prescription Databases of Sweden was accessed to determine the number of individuals by age who had received a prescription for a bone-active medication in 2010. Exposure to oestrogens was not included. Treatment days (daily defined doses; DDD) were computed from the prescription refills in 2010 and converted to person-years of exposure to treatment (DYD). Treatment rates were expressed as a proportion of the Swedish population [1].

Results

The numbers of individuals by age who had received bone-active medication and the DYDs are shown in Table 45. Treatment uptake is expressed as the number of individuals who were taking a bone-active medication (i.e. filled a prescription) and the number of person-years of treatment in that year. For example, there were 18,931 men and women aged 80–84 years who had been prescribed a treatment in 2010. The total prescription base for that age range was equivalent to 13,888 person-years. Over all ages, 3 % of the Swedish population aged 50 years or more received treatment.

Figure 34 shows the uptake of bone-active agents (oestrogens excluded) for 2010. For example, there were 77 prescriptions filled per 1,000 of the population aged 80–85 years in 2010. The number of unique patients that received a prescription for that age range was 56 per 1,000 person-years. These figures are low when compared with the population at high risk. For example, the number of patients in this age range that received a treatment was approximately 13,500 representing

4d National prescription database

Domain

Service uptake—Background information

Background and aims

IMS Health provides sales data that can be examined by country but give no information on who receives the agent in question or the purpose for which it was given (see Chapter 4c). Such data are not available on an EU-wide basis. However, several EU countries have a National Prescription Database that can provide more detailed information.

Table 45 Population size, patients treated and patient-years of treatment by age in Sweden 2010

Age (years)	Population (000)	Patients treated	Patient-years of treatment	DYD
50–54	577	2,347	1,779	1,779
55–59	573	5,328	3,953	3,953
60–64	626	10,346	7,665	7,665
65–69	535	15,685	11,693	11,693
70–74	378	17,081	12,659	12,659
75–79	303	18,802	14,055	14,055
80–84	247	18,931	13,888	13,888
85+	249	16,883	12,394	12,394
50+	3,488	105,403	78,086	




Fig. 34 The number (rate/thousand) of prescriptions for bone-active medications and the number of patients filling a prescription for bone-active medications in 2010 [National Prescription Databases of Sweden]

5.6 % of the population at this age. In contrast, the number of individuals in this age range with osteoporosis is estimated at 67,800 and those with a fracture probability above a fracture threshold is estimated at 32,000 [2]. Thus, although treatments are targeted by age, the majority of high risk individuals remain untreated.

Score allocation

None—supplementary information

Comment

Note that the data do not give information on persistence or compliance. Although treatments are targeted by age, the majority of high risk individuals remain untreated.

References

1. UN (2010) Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat (2010) World Population Prospects: The 2010 Revision, <http://esa.un.org/unpd/wpp/index.htm> Accessed 16th December 2011
2. Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jönsson B (2011) Osteoporosis; Burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59–155

4e Treatment gap and treatment need

Domain

Service uptake—Background information

Background and aims

Patients who sustain a prior fragility fracture are at great risk of a future fracture. The risk is increased approximately two-fold [1] and is largely independent of BMD [2]. The risk is sufficiently high that many treatment guidelines in the EU recommend that postmenopausal women with a prior fragility fracture should be offered treatment. However, the majority of such patients are untreated so that the prevalence of a prior fracture in the community provides an index of opportunity lost. This may be set against the treatment gap to provide an index of the relationship between service provision and service need. The aim of this element was to provide an index of the prevalence of a prior fracture in the EU member countries in relation to the treatment gap.

Methods

For the purposes of this report, a prior fracture was defined as a hip or clinical vertebral fracture in an individual who was alive in 2010 that had occurred after the age of 50 years before 2010. The unit was the individual so that multiple fractures at the same site in one individual were only counted as one prior fracture of that site. A micro-simulation model, programmed in TreeAge, was used to simulate the prevalence of prior hip and vertebral fractures from incidence data [3]. Note that the prevalence of a hip or clinical vertebral fracture will underestimate the prevalence of previous fragility fracture at other sites.

More complete information on prior fractures is available for six member states (France, Germany, Italy, Spain, Sweden and the UK) using a different approach [4] and is also considered.

For the treatment gap, the data from Chapter 4c were used [1].

Results

In 2010, approximately 6.7 million men and women in the EU had sustained a prior hip or clinical spine fracture before 2010 (Table 46). As would be expected, the prevalence increased progressively with age. At the age of 95 years or more, the prevalence of a prior hip fracture was 22.5 % and for a prior vertebral fracture was 14.5 % [1]. Overall, 1.8 % of the population at the age of 50 years or more had a prior hip fracture and 1.9 % a prior clinical spine fracture.

Table 46 Estimated number and percentage of men and women aged above 50 years with a prior hip or vertebral fracture by country in 2010 [3]

	Hip fracture		Vertebral fracture		A+B
	Number	% Population (A)	Number	% Population (B)	
Austria	74,270	2.4	83,623	2.7	5.1
Belgium	74,485	1.9	80,706	2.0	3.9
Bulgaria	31,370	1.1	32,780	1.1	2.2
Cyprus	4,921	1.6	6,150	2.0	3.6
Czech	58,979	1.6	64,340	1.7	3.3
Denmark	49,746	2.5	58,573	2.9	5.4
Estonia	7,350	1.5	7,486	1.5	3.0
Finland	34,181	1.6	37,192	1.8	3.4
France	434,674	1.9	435,507	1.9	3.8
Germany	669,799	2.0	775,529	2.3	4.3
Greece	87,413	2.1	101,760	2.4	4.5
Hungary	57,225	1.6	60,594	1.6	3.2
Ireland	17,247	1.4	18,742	1.5	2.9
Italy	517,126	2.2	539,036	2.3	4.5
Latvia	11,862	1.5	11,575	1.4	2.9
Lithuania	13,046	1.2	12,782	1.1	2.3
Luxemburg	2,446	1.5	2,790	1.8	3.3
Malta	1,974	1.3	2,316	1.5	2.8
Netherlands	74,594	1.3	82,206	1.4	2.7
Poland	139,212	1.0	144,863	1.1	2.1
Portugal	52,106	1.3	53,653	1.4	2.7
Romania	72,024	1.0	82,829	1.1	2.1
Slovakia	28,065	1.6	32,488	1.9	3.5
Slovenia	12,429	1.6	14,306	1.9	3.5
Spain	210,560	1.3	212,428	1.3	2.6
Sweden	98,952	2.8	111,348	3.2	6.0
UK	418,881	1.9	437,499	2.0	3.9
EU27	3,254,939	1.8	3,503,101	1.9	3.7

The ranked prevalences by country are shown in Fig. 35. As would be expected, there was a close relationship between fracture risk (see Chapter 1b) and the proportion of the population with a prior hip or clinical vertebral fracture.

Table 47 summarises data for the EU5+Sweden which shows the prevalence of *all prior fractures* in 2010 in comparator studies. The estimation of prior vertebral + prior hip fracture, shown in Fig. 35, appears to capture approximately 30 % of prior fractures. This suggests that the prevalence of a prior clinical spine or hip fracture is a reasonable surrogate for the service needs of each member state.

The relationship between this service need and the treatment gap is shown in Fig. 36 for each of the EU member states and for the EU countries combined. The top right quadrant can be considered to represent countries of high need but poor provision. These included Denmark and Sweden. The other extreme (lower left quadrant) represents countries of lower need




Fig. 35 The proportion (%) of the population aged 50 years or more with a prior hip or vertebral fracture in 2010 [3]

Table 47 The prevalence (%) of a prior fracture at sites associated with osteoporosis in men and women aged 50 years or more compared with the prevalence of a prior vertebral or hip fracture as given in Table 46. The last column shows the proportion (%) of prior fractures accounted for by hip or clinical vertebral fracture [3]

Country	Author	Prevalence (%)		EU/C
		Comparator	EU27	
France	Cawston 2012 [5]	11.2	3.8	34
Germany	Gauthier 2012 [6]	14.1	4.3	30
Italy	Piscitelli 2012 [7]	16.2	4.5	28
Spain	Gauthier 2012 [8]	8.9	2.6	29
Sweden	Gauthier 2011 [4]	22.6	6.0	27
UK	Gauthier 2011[9]	10.3	3.9	39
Average				30

but better provision. These included Estonia, Ireland Hungary and Spain.

Score allocation

Supplementary information, no score allocation




Fig. 36 The relationship between the prevalence of a prior spine or hip fracture (service need) and the treatment gap (service provision) in the EU27 countries. The horizontal and vertical lines intersect at the EU average (weighted for population size) [3]. Country codes (ISO 3166-1 alpha-2); AT Austria; BE Belgium; BG Bulgaria; CY Cyprus; CZ Czech Republic; DE Germany; DK Denmark; EE Estonia; ES Spain; FI Finland; FR France; GB United Kingdom; GR Greece; HU Hungary; IE Ireland; IT Italy; LT Lithuania; LU Luxembourg; LV Latvia; MT Malta; NL Netherlands; PL Poland; PT Portugal; RO Romania; SE Sweden; SI Slovenia; SK Slovakia

Comment

There is a wide variation in both (hip and spine) fractures and treatment gap between countries. This is of particular concern in countries with a high fracture burden and a high treatment gap.

References

1. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, III, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. *J Bone Miner Res* 15: 721–39
2. Kanis JA, Johnell O, De Laet C et al. (2004) A meta-analysis of previous fracture and subsequent fracture risk. *Bone* 35: 375–82
3. Hernlund E, Svedbom A, Ivergård M Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos*, in press
4. Gauthier A, Kanis JA, Martin M, Compston J, Borgström F, Cooper C, McCloskey E; Committee of Scientific Advisors, International Osteoporosis Foundation (2011) Development and validation of a disease model for postmenopausal osteoporosis. *Osteoporos Int* 22: 771–80.
5. Cawston H, Maravic M, Fardellone P et al. (2013) Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model *Arch Osteoporos*. 7: 237–46
6. Gauthier A, Kanis JA, Jiang Y, Dreinhöfer K, Martin M, Compston J, Borgström F, Cooper C, McCloskey E (2013) Burden of postmenopausal osteoporosis in Germany: estimations from a disease model. *Arch Osteoporos* 7:209–18
7. Piscitelli P, Brandi M, Cawston H, Gauthier A, Kanis JA, Compston J, Borgström F, Cooper C, McCloskey E (2012) Epidemiological burden of postmenopausal osteoporosis in Italy from 2010 to 2020: Estimations from a disease model. Unpublished.
8. Gauthier A, Kanis JA, Jiang Y, Cannata J, Compston J, Borgström F, Cooper C, McCloskey E (2012) Burden of post-menopausal osteoporosis in Spain: Estimations from a disease model. Unpublished
9. Gauthier A, Kanis JA, Jiang Y, Martin M, Compston J, Borgström F, Cooper C, McCloskey E (2011) Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: Estimations from a Disease Model. *Arch Osteoporos* 6: 179–188

4f Waiting time for hip surgery

Domain

Service uptake—scorecard element

Background and aims

About 5 % of people with a hip fracture die within 1 month and about one quarter within 12 months. Most

deaths are due to associated conditions and not to the fracture itself [1], reflecting the high prevalence of comorbidity. In the EU27, hip fractures were estimated to result in approximately 11,000 premature deaths in women that were directly attributable to the fracture event in 2010. The corresponding numbers for men were estimated at approximately 9,000 [2]. A determinant of peri-operative morbidity and mortality is the time a patient takes to get to surgery which, in turn, is an early marker of a patient's progress following a hip fracture. Early surgery (<48 h) is associated with a statistically and clinically significant reduction in mortality at 1 year and an increase in the proportion of patients returning to their original residence [3].

The aim of this scorecard element was to determine average waiting times for hip surgery in the EU member states.

Methods

Data were acquired by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012. Respondents were asked to provide information on the average waiting time for hip surgery after hip fracture. Countries were categorised according to average waiting times between hospital admission and surgical intervention. An additional indicator of management that was sought was the proportion of hip fracture cases that were managed surgically.

Results

Waiting times between admission to hospital and surgical intervention were on average 1 day or less in 7 countries, 1–2 days in 13 countries and greater than 2 days in 6 countries (Table 48). Information was not recorded for Malta. More than 90 % of hip fracture cases received surgery in the majority of countries. Exceptions included Bulgaria, Czech Republic, Hungary and Italy where 75–90 % of cases received a surgical intervention.

Score criteria and allocation

Uptake was categorised by average waiting time for hip surgery (Table 49)

Score allocation

Score results are given in Table 48 and colour coded in Fig. 37.

Table 48 Average waiting times between hospital admission and surgical intervention and the proportion of hip fracture cases managed surgically [IOF audit]





	Waiting time (days)	Surgical management (%)	Score
Austria	1–2	>90	2
Belgium	<1	>90	3
Bulgaria	1–2	75–90	2
Cyprus	2–3	>90	1
Czech Republic	1–2	75–90	2
Denmark	1–2	>90	2
Estonia	<1	>90	3
Finland	1–2	>90	2
France	1–2	>90	2
Germany	<1	>90	3
Greece	2–3	>90	1
Hungary	<1	75–90	3
Ireland	2–3	>90	1
Italy	2–3	75–90	1
Latvia	<1	>90	3
Lithuania	<1	>90	3
Luxembourg	1–2	>90	2
Malta	nr	nr	
Netherlands	1–2	>90	2
Poland	1–2	>90	2
Portugal	2–3	>90	1
Romania	1–2	>90	2
Slovakia	1–2	>90	2
Slovenia	1–2	>90	2
Spain	2–3	>90	1
Sweden	<1	>90	3
UK	1–2	>90	2

nr, not recorded

Comment

Note that average waiting times give no index of the dispersion around the mean

Table 49 Criteria for allocating scores

Score		Criterion
3		Average, less than 1 day
2		Average, 1 – 2 days
1		Average, more than 2 days
0		No data recorded

Waiting time for hip surgery (days)




Fig. 37 Countries categorised by the average waiting time for surgical intervention for hip fracture [IOF audit]


References

1. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. *Bone* 32; 468–473.
2. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos*, in press
3. National Clinical Guideline Centre, (2011) The Management of Hip Fracture in Adults. London: National Clinical Guideline Centre. Available from: www.ncgc.ac.uk Accessed Jan 2013

The scorecard

SCOPE. The Scorecard for Osteoporosis in Europe, is an innovative tool that allows health and policy professionals to

assess key indicators on the healthcare provision for osteoporosis in countries and between counties within the EU.



Scorecard key

Title	Description	Units	Score			
1. Burden of disease						
1d. Hip fracture risk	The age-standardised incidence of hip fracture in women	rate/100,000	<300	300-400	400+	unknown
1e. Fracture risk	All osteoporotic fractures in men and women	rate/1000 >50 years	<15	15-20	>20	
1f. Lifetime risk	Remaining lifetime risk of hip fracture (women aged 50y)	%.	<13	13-18	>18	unknown
1g. FRAX risk	Men and women with a > 10% ten year probability of a major fracture	% in 50-89 y age range	<20	20-25	>25	
1i. Fracture projections	Increase in fracture number 2010-2025	% >50 years	0-25	26-33	>33	
2. Policy framework						
2a. Quality of data	Data on hip fracture rates	Score	-	-	-	
2b National health care priority	The presence of government backed NHP	Score	-	-	-	
2c. Care pathway	Management in primary care	Score	-	-	-	
2d Specialist training	Osteoporosis an established specialty.	Score	-	-	-	
2e. Society support	Patient support societies	Score	-	-	-	
3. Service provision						
3a. Treatment	Reimbursement and problems that arise	Score	-	-	-	
3b. Availability of DXA	Number of DXA units available	Units/m of the general population	>18	8.4-18	<8.4	
3c. Access to DXA	Reimbursement and problems that arise	Score	-	-	-	
3d. Risk models	Availability of country-specific risk models and guidance	Score	-	-	-	
3e. Guideline quality	Quality and scope of guidelines for assessment and treatment	Score	-	-	-	none
3g. Liaison services	Provision for fracture liaison services	Score	-	-	-	unknown
3h. Quality indicators	Presence and use of quality indicators	Score	-	-	-	
4. Service uptake						
4b. Risk models	FRAX calculations	/million of the general population/year	>1200	320-1200	<320	
4c. Treatment gap	Proportion of women at high risk who are untreated	% >50y	<45	45-65	>65	unknown
4f. Waiting time	Average waiting time for hip surgery	days	<1	1-2	>2	unknown

Competing interests The panel has received speaker fees, advisory board fees and/or unrestricted research grants from governmental and non-governmental sources. A full list of disclosures is available from the International Osteoporosis Foundation upon request.

Acknowledgments SCOPE was supported by an unrestricted grant from Amgen and GlaxoSmithKline (GSK). Neither company was involved in the design or writing of the report. We are grateful to Carey Kyer of the International Osteoporosis Foundation for the administration of the IOF questionnaire for her help with formatting and editing the report and to Gilberto Lontro of the International Osteoporosis Foundation for designing the scorecard. We thank Robert McGruer, Simone Boselli of Hill & Knowlton for their support services. Prof F Hooven, University of Massachusetts Medical School and B Abrahamsen, University of Southern Denmark kindly supplied previously unpublished data for use in this report. We are grateful to H Sundseth (European Institute of Women's Health) for her help in the early phase of this project. We are grateful for the help provided by the National Societies of the IOF based in the EU, listed below for updating the information base of the European audit 'Osteoporosis in the European Union in 2008: Ten years of progress and ongoing challenges'. Finally, we thank the Committee of Scientific Advisors of the IOF their review and endorsement of this report.

Austria	Austrian Society for Bone and Mineral Research (AUSBMR) Action for Healthy Bones Austrian Menopause Society National Osteoporosis Patient Society Austria
Belgium	The Royal Belgian Rheumatology Society Belgian Bone Club
Bulgaria	Bulgarian Society for Clinical Densitometry Association Women without Osteoporosis Bulgarian League for the Prevention of Osteoporosis-blpo Bulgarian Medical Society of Osteoporosis and Osteoarthritis
Cyprus	Cyprus Society for Osteoporosis Cyprus Society against Osteoporosis and Myoskeletal Diseases
Czech Republic	Osteologic Academy zlin Czech Osteoporosis League Czech Society for Metabolic Skeletal Diseases (SMOS)
Denmark	National Osteoporosis Foundation Denmark Danish Bone Society
Estonia	Estonian Osteoporosis Society
Finland	Finnish Bone Society Finnish Osteoporosis Association
France	French League Against Rheumatism (AFLAR) French Society of Orthopaedic And Trauma Surgery (SOFOT) French Society For Clinical Densitometry (SO.F.O.C.) Research And Information Group On Osteoporosis (GRIO)
Germany	German Osteoporosis Patient Society (BFO) Osteoporose Selbsthilfegruppen Dachverband E.V (OSD) Netzwerk-osteoporose e.v German Society For Endocrinology (DGE)

Greece	Committee For Healthy Bones– Kuratorium Knochengesundheit Orthopädische Gesellschaft Für Osteologie (OGO) Hellenic Society For The Study Of Bone Metabolism Hellenic Foundation Of Osteoporosis Hellenic Society Of Osteoporosis Patient Support Hellenic Endocrine Society - Panhellenic Association Of Endocrinologists
Hungary	Hungarian Osteoporosis Patients Association (HOPA) Hungarian Society For Osteoporosis And Osteoarthritis
Ireland	Irish Osteoporosis Society (IOS)
Italy	Italian Association Of Osteoporosis Patients Italian Foundation For Research On Osteoporosis And Musculoskeletal Diseases - FIROMMS Italian COPD Patient Association Osteoporosis Italian Association - Osteo Stop Italian Society For Osteoporosis Mineral Metabolism And Skeletal Diseases (SIOMMMS) Italian Federation Of Osteoporosis And Diseases Of The Skeleton (FEDIOS) Italian Osteoporosis League (LIOS) Italian Society Of Rheumatology
Latvia	Latvia Osteoporosis Patient And Invalid Association Latvian Osteoporosis And Bone Metabolism Diseases Association
Lithuania	Lithuanian Osteoporosis Foundation Lithuanian Association Of Metabolic Bone Diseases Incorporated In Lithuanian Endocrine Society
Luxembourg	Association luxembourgeoise d'étude du métabolisme osseux et de l'ostéoporose (ALEMO)
Malta	Malta Osteoporosis Society
Netherlands	Osteoporose Vereniging Osteoporose Stichting - Dutch Osteoporosis Foundation
Poland	Healthy Bone Enthusiasts Society (STENKO) Polish Foundation of Osteoporosis Polish Osteoarthritis Society Multidisciplinary Osteoporotic Forum
Portugal	Portuguese Osteoporosis Association (APO) Portuguese Society Of Osteoporosis And Other Metabolic Bone Diseases (SPODOM) National Association Against Osteoporosis (APOROS)
Romania	Romanian Society Of Rheumatology Association For Prevention Of Osteoporosis In Romania (ASPOR) Romanian Society Of Osteoporosis And Musculoskeletal Diseases Romanian Foundation Of Osteoarthritis (OSART)
Slovakia	Slovak Union Against Osteoporosis Slovak Society Osteoporosis & Metabolic Bone Diseases
Slovenia	Slovene Bone Society Slovene Osteoporosis Patients Society
Spain	Spanish Society for Rheumatology

Spain	Spanish Society for Research on Bone and Mineral Metabolism (SEIOMM)	DXA	Dual-energy X-ray absorptiometry, a method for measuring BMD
	Hispanic Foundation Of Osteoporosis And Metabolic Bone Diseases (FHOEMO)		
	Spanish Association Against Osteoporosis (AECOS)		
	Spanish Society of Osteoporotic Fractures		
Sweden	1.6 million club	EFPIA	European Federation of Pharmaceutical Industries Association
	Swedish Osteoporosis Patient Society (ROP)		
	Swedish Rheumatism Association		
	Swedish Osteoporosis Society		
UK	The Bone Research Society	EU27	The 27 member states of the European Union
	National Osteoporosis Society (NOS)		
Multinational	International Osteoporosis Foundation (IOF)	FRAX	Fracture risk assessment tool developed by the WHO Collaborating Centre, University of Sheffield Medical School, UK. FRAX calculates the 10-year probability of a major osteoporotic fracture and hip fracture in individuals from clinical risk factors and BMD
	Umbrella organisation of German speaking osteoporosis patient societies (DOP)		
	Umbrella organisation of German speaking societies of osteology (DVO)		
	European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)		
	Deutsche Gesellschaft für Osteologie		
	International Society For Fracture Repair (ISFR)		
	Mediterranean Society For Osteoporosis And Other Skeletal Diseases (MSOSD)		
	Ibero American Society of Osteology and Mineral Metabolism (SIBOMM)		
	European Union Geriatrics Medicine (EUGMS)		
	European Calcified Tissue Society (ECTS)		

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Abbreviations and glossary

BMD	Bone mineral density, usually measured as the amount of calcium in bone per unit area.	Probability	The likelihood of an event, e.g. fracture. Fracture probability depends on two hazards—the incidence of fracture and the incidence of death
BMI	Body mass index, an index of leanness or obesity measured from height and weight	QALY	The QALY is a multi-dimensional outcome measure that incorporates both the quality (health related) and quantity (length) of life. The value of a QALY was set at value of 2× GDP per capita
CI	Confidence interval	QCT	Quantitative computed tomography
CRF	Clinical risk factor, in this context for fracture	QoL	Quality of life
DALY	Disability-adjusted life year, a product of years of life lost and the remaining years of life disabled (i.e., disutility).	QUS	Quantitative ultrasound
DDD	Defined daily dosage	SCOPE	Scorecard for osteoporosis in Europe
Direct costs	Used in health technology assessment to describe direct healthcare costs (e.g., hospital admissions, medical examinations, drug therapy, etc.), the indirect costs (e.g., losses in productivity resulting from absence	SD	Standard deviation
		T score	Describes the number of standard deviations (SD) by which the BMD in an individual differs from the mean value expected in young healthy

	women. The operational definition of osteoporosis is defined as a value for BMD 2.5 SD or more below the young female adult mean (<i>T</i> score less than or equal to -2.5 SD).		
WHO	World Health Organization	WTP	Willingness to pay, used in Health Technology assessment to describe the value that society or a health care payer is prepared to pay to gain a QALY. The value of a QALY was set at value of $2 \times$ GDP per capita.